1
|
How-Kit A, Sahbatou M, Hardy LM, Tessier NP, Schiavon V, Le Buanec H, Sebaoun JM, Blanché H, Zagury JF, Deleuze JF. The CEPH aging cohort and biobank: a valuable collection of biological samples from exceptionally long-lived French individuals and their offspring for longevity studies. GeroScience 2024; 46:2681-2695. [PMID: 38141157 PMCID: PMC10828222 DOI: 10.1007/s11357-023-01037-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Accepted: 12/06/2023] [Indexed: 12/24/2023] Open
Abstract
The increasing aging of the human population is currently and for the coming decades a major public health issue in many countries, requiring the implementation of global public health policies promoting healthy and successful aging. Individuals are not equal in the face of aging and some can present exceptional healthspan and/or lifespan, which are notably influenced by both genetic and environmental factors. Research and studies on human aging, healthy aging and longevity should rely in particular on cohorts of long-lived individuals, also including biological samples allowing studies on the biology of aging and longevity. In this manuscript, we provide for the first time a complete description of the CEPH (Centre d'Etude du Polymophisme Humain) Aging cohort, an exceptional cohort recruited during the 90s to 2000s, including more than 1700 French long-lived individuals (≥ 90 years old) born between 1875 and 1916 as well as for some of them their siblings and offspring. Among the participants, 1265 were centenarians, including 255 semi-supercentenarians ([105-110] years old) and 25 supercentenarians (≥ 110 years old). The available anthropometric, epidemiologic and clinical data for the cohort participants are described and especially the collection of blood-derived biological samples associated with the cohort which includes DNA, cryopreserved cells and cell lines, plasma, and serum. This biological collection from the first cohort of centenarians in the world is an inestimable resource for ongoing and future molecular, cellular, and functional studies aimed at deciphering the mechanisms of human (successful) aging and longevity.
Collapse
Affiliation(s)
- Alexandre How-Kit
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France.
- Laboratory of Excellence GenMed, Paris, France.
| | - Mourad Sahbatou
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France
| | - Lise M Hardy
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France
- Laboratory of Excellence GenMed, Paris, France
| | - Nicolas P Tessier
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France
- Laboratory of Excellence GenMed, Paris, France
| | - Valérie Schiavon
- INSERM U976 - HIPI Unit, Saint-Louis Research Institute, University of Paris, Paris, France
| | - Hélène Le Buanec
- INSERM U976 - HIPI Unit, Saint-Louis Research Institute, University of Paris, Paris, France
| | - Jean-Marc Sebaoun
- Centre de Ressources Biologiques, Foundation Jean Dausset - CEPH, Paris, France
| | - Hélène Blanché
- Laboratory of Excellence GenMed, Paris, France
- Centre de Ressources Biologiques, Foundation Jean Dausset - CEPH, Paris, France
| | - Jean-François Zagury
- Équipe Génomique, Bioinformatique et Chimie Moléculaire (EA 7528), Conservatoire National Des Arts et Métiers, HESAM Université, Paris, France
| | - Jean-François Deleuze
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France.
- Laboratory of Excellence GenMed, Paris, France.
- Centre de Ressources Biologiques, Foundation Jean Dausset - CEPH, Paris, France.
- Centre National de Recherche en Génomique Humaine, CEA, Institut François Jacob, Evry, France.
| |
Collapse
|
2
|
Suver C, Harper J, Loomba J, Saltz M, Solway J, Anzalone AJ, Walters K, Pfaff E, Walden A, McMurry J, Chute CG, Haendel M. The N3C governance ecosystem: A model socio-technical partnership for the future of collaborative analytics at scale. J Clin Transl Sci 2023; 7:e252. [PMID: 38229902 PMCID: PMC10789985 DOI: 10.1017/cts.2023.681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 09/22/2023] [Accepted: 11/06/2023] [Indexed: 01/18/2024] Open
Abstract
The National COVID Cohort Collaborative (N3C) is a public-private-government partnership established during the Coronavirus pandemic to create a centralized data resource called the "N3C data enclave." This resource contains individual-level health data from participating healthcare sites nationwide to support rapid collaborative analytics. N3C has enabled analytics within a cloud-based enclave of data from electronic health records from over 17 million people (with and without COVID-19) in the USA. To achieve this goal of a shared data resource, N3C implemented a shared governance strategy involving stakeholders in decision-making. The approach leveraged best practices in data stewardship and team science to rapidly enable COVID-19-related research at scale while respecting the privacy of data subjects and participating institutions. N3C balanced equitable access to data, team-based scientific productivity, and individual professional recognition - a key incentive for academic researchers. This governance approach makes N3C research sustainable and effective beyond the initial days of the pandemic. N3C demonstrated that shared governance can overcome traditional barriers to data sharing without compromising data security and trust. The governance innovations described herein are a helpful framework for other privacy-preserving data infrastructure programs and provide a working model for effective team science beyond COVID-19.
Collapse
Affiliation(s)
- Christine Suver
- Research Governance & Ethics, Sage Bionetworks, Seattle, WA, USA
| | | | - Johanna Loomba
- Integrated Translational Health Research Institute of Virginia (iTHRIV), University of Virginia, Charlottesville, VA, USA
| | - Mary Saltz
- Department of Biomedical Informatics, Stony Brook University, New York, NY, USA
| | - Julian Solway
- Institute for Translational Medicine, University of Chicago, Chicago, IL, USA
| | - Alfred Jerrod Anzalone
- Department of Neurological Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | | | - Emily Pfaff
- University of North Carolina, Chapel Hill, NC, USA
| | - Anita Walden
- Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Julie McMurry
- Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Christopher G. Chute
- Schools of Medicine, Public Health, and Nursing, Johns Hopkins University, Baltimore, MD, USA
| | - Melissa Haendel
- Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| |
Collapse
|
3
|
Croxton T, Jonathan E, Suleiman K, Balogun O, Ozumba PJ, Aloyo SM, Nsubuga G, Kamulegeya RE, Newton L, Mukisa J, Kader M, Damaneite V, Nadoma S, Onyemata EJ, Anzaku AA, Nasinghe E, Troyer J, Joubert BR, Beiswanger C, Joloba ML, Mayne E, Abimiku A. Building blocks for better biorepositories in Africa. Genome Med 2023; 15:92. [PMID: 37932809 PMCID: PMC10626646 DOI: 10.1186/s13073-023-01235-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Accepted: 09/19/2023] [Indexed: 11/08/2023] Open
Abstract
BACKGROUND Biorepositories archive and distribute well-characterized biospecimens for research to support the development of medical diagnostics and therapeutics. Knowledge of biobanking and associated practices is incomplete in low- and middle-income countries where disease burden is disproportionately high. In 2011, the African Society of Human Genetics (AfSHG), the National Institutes of Health (NIH), and the Wellcome Trust founded the Human Heredity and Health in Africa (H3Africa) consortium to promote genomic research in Africa and established a network of three biorepositories regionally located in East, West, and Southern Africa to support biomedical research. This manuscript describes the processes established by H3Africa biorepositories to prepare research sites to collect high-quality biospecimens for deposit at H3Africa biorepositories. METHODS The biorepositories harmonized practices between the biorepositories and the research sites. The biorepositories developed guidelines to establish best practices and define biospecimen requirements; standard operating procedures (SOPs) for common processes such as biospecimen collection, processing, storage, transportation, and documentation as references; requirements for minimal associated datasets and formats; and a template material transfer agreements (MTA) to govern biospecimen exchange. The biorepositories also trained and mentored collection sites in relevant biobanking processes and procedures and verified biospecimen deposit processes. Throughout these procedures, the biorepositories followed ethical and legal requirements. RESULTS The 20 research projects deposited 107,982 biospecimens (76% DNA, 81,067), in accordance with the ethical and legal requirements and established best practices. The biorepositories developed and customized resources and human capacity building to support the projects. [The biorepositories developed 34 guidelines, SOPs, and documents; trained 176 clinicians and scientists in over 30 topics; sensitized ethical bodies; established MTAs and reviewed consent forms for all projects; attained import permits; and evaluated pilot exercises and provided feedback. CONCLUSIONS Biobanking in low- and middle-income countries by local skilled staff is critical to advance biobanking and genomic research and requires human capacity and resources for global partnerships. Biorepositories can help build human capacity and resources to support biobanking by partnering with researchers. Partnerships can be structured and customized to incorporate document development, ethics, training, mentorship, and pilots to prepare sites to collect, process, store, and transport biospecimens of high quality for future research.
Collapse
Affiliation(s)
- Talishiea Croxton
- I-HAB, Institute of Human Virology Nigeria, Abuja, Nigeria.
- University of Maryland School of Medicine, Institute of Human Virology, University of Maryland Baltimore, 725 West Lombard Street Suite, Baltimore, MD, USA.
| | | | | | | | | | - Sharley M Aloyo
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - Gideon Nsubuga
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - Rogers E Kamulegeya
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - Lwanga Newton
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - John Mukisa
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - Mukthar Kader
- Clinical Laboratory Services, Wits Diagnostic Innovation Hub, University of the Witwatersrand, Johannesburg, South Africa
| | - Vuyo Damaneite
- Clinical Laboratory Services, Wits Diagnostic Innovation Hub, University of the Witwatersrand, Johannesburg, South Africa
| | - Sunji Nadoma
- I-HAB, Institute of Human Virology Nigeria, Abuja, Nigeria
| | | | | | - Emmanuel Nasinghe
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - Jennifer Troyer
- National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Bonnie R Joubert
- National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC, USA
| | - Christine Beiswanger
- University of Maryland School of Medicine, Institute of Human Virology, University of Maryland Baltimore, 725 West Lombard Street Suite, Baltimore, MD, USA
| | - Moses L Joloba
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - Elizabeth Mayne
- Division of Immunology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, National Health Laboratory Service, Johannesburg, South Africa
| | - Alash'le Abimiku
- I-HAB, Institute of Human Virology Nigeria, Abuja, Nigeria
- University of Maryland School of Medicine, Institute of Human Virology, University of Maryland Baltimore, 725 West Lombard Street Suite, Baltimore, MD, USA
| |
Collapse
|
4
|
Truong TN, Pham TND, Hoang LB, Nguyen VT, Dao HV, Dao DVB, Alessy S, Pham HB, Pham TTT, Nguyen LDD, Nguyen K, Abaalkhail F, Manal M, Mawardi M, AlZahrani M, Alswat K, Alghamdi H, Sanai FM, Siddiqui MA, Nguyen NH, Vaidya D, Phan HT, Johnson PJ, Alqahtani SA, Dao DY. Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-score. BMC Cancer 2023; 23:875. [PMID: 37723439 PMCID: PMC10506187 DOI: 10.1186/s12885-023-11167-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Accepted: 07/11/2023] [Indexed: 09/20/2023] Open
Abstract
BACKGROUND Vietnam and Saudi Arabia have high disease burden of primary hepatocellular carcinoma (HCC). Early detection in asymptomatic patients at risk for HCC is a strategy to improve survival outcomes in HCC management. GALAD score, a serum-based panel, has demonstrated promising clinical utility in HCC management. However, in order to ascertain its potential role in the surveillance of the early detection of HCC, GALAD needs to be validated prospectively for clinical surveillance of HCC (i.e., phase IV biomarker validation study). Thus, we propose to conduct a phase IV biomarker validation study to prospectively survey a cohort of patients with advanced fibrosis or compensated cirrhosis, irrespective of etiologies, using semi-annual abdominal ultrasound and GALAD score for five years. METHODS We plan to recruit a cohort of 1,600 patients, male or female, with advanced fibrosis or cirrhosis (i.e., F3 or F4) and MELD ≤ 15, in Vietnam and Saudi Arabia (n = 800 each). Individuals with a liver mass ≥ 1 cm in diameter, elevated alpha-fetoprotein (AFP) (≥ 9 ng/mL), and/or elevated GALAD score (≥ -0.63) will be scanned with dynamic contrast-enhanced magnetic resonance imaging (MRI), and a diagnosis of HCC will be made by Liver Imaging Reporting and Data System (LiRADS) assessment (LiRADS-5). Additionally, those who do not exhibit abnormal imaging findings, elevated AFP titer, and/or elevated GALAD score will obtain a dynamic contrast-enhanced MRI annually for five years to assess for HCC. Only MRI nearest to the time of GALAD score measurement, ultrasound and/or AFP evaluation will be included in the diagnostic validation analysis. MRI will be replaced with an abdominal computed tomography scan when MRI results are poor due to patient conditions such as movement etc. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MRI will not be carried out in study sites in both countries. Bootstrap resampling technique will be used to account for repeated measures to estimate standard errors and confidence intervals. Additionally, we will use the Cox proportional hazards regression model with covariates tailored to the hypothesis under investigation for time-to-HCC data as predicted by time-varying biomarker data. DISCUSSION The present work will evaluate the performance of GALAD score in early detection of liver cancer. Furthermore, by leveraging the prospective cohort, we will establish a biorepository of longitudinally collected biospecimens from patients with advanced fibrosis or cirrhosis to be used as a reference set for future research in early detection of HCC in the two countries. TRIAL REGISTRATION Name of the registry: ClinicalTrials.gov Registration date: 22 April 2022 Trial registration number: NCT05342350 URL of trial registry record.
Collapse
Affiliation(s)
- Thai Ngoc Truong
- Department of Internal Medicine, Hanoi Medical University, Hanoi, Vietnam
| | - Trang Ngoc Doan Pham
- School of Public Health, the University of Illinois in Chicago, Chicago, IL, USA
| | - Long Bao Hoang
- Institute of Gastroenterology and Hepatology, Hanoi, Vietnam
| | - Van Thi Nguyen
- Institute of Gastroenterology and Hepatology, Hanoi, Vietnam
| | - Hang Viet Dao
- Department of Internal Medicine, Hanoi Medical University, Hanoi, Vietnam
- Institute of Gastroenterology and Hepatology, Hanoi, Vietnam
| | | | - Saleh Alessy
- College of Health Sciences, the Saudi Electronic University, Jeddah, Saudi Arabia
| | | | | | - Linh Duc Duy Nguyen
- Medic Medical Center in Rach Gia, Rach Gia City, Kien Giang Province, Vietnam
| | - Khue Nguyen
- Medic Medical Center in Ca Mau, Ca Mau City, Vietnam
| | - Faisal Abaalkhail
- Department of Medicine, Section of Gastroenterology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
- College of Medicine, Al-Faisal University, Riyadh, Saudi Arabia
| | - Mohammed Manal
- Department of Internal Medicine, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
| | - Mohammad Mawardi
- Department of Internal Medicine, King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia
| | - May AlZahrani
- Department of Internal Medicine, King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia
| | - Khalid Alswat
- Liver Disease Research Center, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | | | - Faisal M Sanai
- Gastroenterology Unit, Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Mohammed Amir Siddiqui
- Gastroenterology Unit, Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | | | - Dhananjay Vaidya
- The BEAD Core (Biostatistics, Epidemiology, and Data Management), Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Hai Thanh Phan
- Medic Medical Center in Ho Chi Minh, Ho Chi Minh City, Vietnam
| | - Philip J Johnson
- Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
| | - Saleh A Alqahtani
- Division of Gastroenterology & Hepatology, Johns Hopkins University, Baltimore, MD, USA.
- Liver Transplant Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
| | - Doan Y Dao
- Vietnam Viral Hepatitis Alliance, Reston, VA, USA.
- Division of Gastroenterology & Hepatology, Johns Hopkins University, Baltimore, MD, USA.
- Center of Excellence for Liver Disease in Vietnam, Division of Gastroenterology & Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
| |
Collapse
|
5
|
Silver S, Schmelz M. The AIDS and Cancer Specimen Resource (ACSR): HIV malignancy specimens and data available at no cost. AIDS Res Ther 2023; 20:61. [PMID: 37641153 PMCID: PMC10464020 DOI: 10.1186/s12981-023-00558-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Accepted: 08/17/2023] [Indexed: 08/31/2023] Open
Abstract
The goal of the AIDS and Cancer Specimen Resource (ACSR) is to play a major role in the advancement of HIV/AIDS cancer-related research/treatment by providing richly annotated biospecimens and data to researchers at no cost. The ACSR acquires, stores, and equitably distributes these samples and associated clinical data to investigators conducting HIV/AIDS-related research, at no costs. Currently, it is the only biorepository of human biospecimens from people with HIV and cancer available to eligible researchers globally who are studying HIV associated malignancies.This review describes the history and organizational structure of the ACSR, its types of specimens in its inventory, and the process of requesting specimens. In addition, the review provides an overview of research that was performed over the last 5 years with its support and gives a summary of important new findings acquired by this research into the development of cancers in people with HIV, including both Aids-related and non-Aids-related malignancies.
Collapse
Affiliation(s)
- Sylvia Silver
- Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, USA
| | - Monika Schmelz
- Department of Pathology, University of Arizona, 1501 N. Campbell Ave, Tucson, AZ, 85724, USA.
| |
Collapse
|
6
|
Drouet DE, Liu S, Crawford DC. Assessment of multi-population polygenic risk scores for lipid traits in African Americans. PeerJ 2023; 11:e14910. [PMID: 37214096 PMCID: PMC10198155 DOI: 10.7717/peerj.14910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Accepted: 01/25/2023] [Indexed: 05/24/2023] Open
Abstract
Polygenic risk scores (PRS) based on genome-wide discoveries are promising predictors or classifiers of disease development, severity, and/or progression for common clinical outcomes. A major limitation of most risk scores is the paucity of genome-wide discoveries in diverse populations, prompting an emphasis to generate these needed data for trans-population and population-specific PRS construction. Given diverse genome-wide discoveries are just now being completed, there has been little opportunity for PRS to be evaluated in diverse populations independent from the discovery efforts. To fill this gap, we leverage here summary data from a recent genome-wide discovery study of lipid traits (HDL-C, LDL-C, triglycerides, and total cholesterol) conducted in diverse populations represented by African Americans, Hispanics, Asians, Native Hawaiians, Native Americans, and others by the Population Architecture using Genomics and Epidemiology (PAGE) Study. We constructed lipid trait PRS using PAGE Study published genetic variants and weights in an independent African American adult patient population linked to de-identified electronic health records and genotypes from the Illumina Metabochip (n = 3,254). Using multi-population lipid trait PRS, we assessed levels of association for their respective lipid traits, clinical outcomes (cardiovascular disease and type 2 diabetes), and common clinical labs. While none of the multi-population PRS were strongly associated with the tested trait or outcome, PRSLDL-Cwas nominally associated with cardiovascular disease. These data demonstrate the complexity in applying PRS to real-world clinical data even when data from multiple populations are available.
Collapse
Affiliation(s)
- Domenica E. Drouet
- Department of Medicine, Case Western Reserve University, Cleveland, OH, United States of America
| | - Shiying Liu
- Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, United States of America
| | - Dana C. Crawford
- Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, United States of America
- Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, United States of America
- Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, United States of America
| |
Collapse
|
7
|
López JE, Kyle A, Hosseini AJ, Wilson M, Soares S. Educational video while "waiting-to-be-seen" in a cardiology outpatient clinic promotes opt-in self-consent for biobanking of remnant clinical biospecimens: A randomized-controlled trial. J Clin Transl Sci 2023; 7:e103. [PMID: 37250987 PMCID: PMC10225258 DOI: 10.1017/cts.2023.518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 03/12/2023] [Accepted: 03/26/2023] [Indexed: 05/31/2023] Open
Abstract
Objectives Consenting donors for remnant clinical biospecimen donation is critical for scaling research biorepositories. Opt-in, low-cost, self-consenting for donations that solely relied on clinical staff and printed materials was recently shown to yield ∼30% consent rate. We hypothesized that adding an educational video to this process would improve consent rates. Methods Randomized patients (by clinic day) in a Cardiology clinic received either printed materials (control) or the same materials plus an educational video on donations (intervention) while waiting to be seen. Engaged patients were surveyed at the clinic checkout for an "opt-in" or "opt-out" response. The decision was documented digitally in the electronic medical record. The primary outcome of this study was the consent rate. Results Thirty-five clinic days were randomized to intervention (18) or control (17). Three hundred and fifty-five patients were engaged, 217 in the intervention and 158 in the control. No significant demographic differences were noted between treatment groups. Following an intention-to-treat analysis, the rate of opt-in for remnant biospecimen donation was 53% for the intervention and 41% for the control group (p-value = 0.03). This represents a 62% increase in the odds of consenting (OR = 1.62, 95% CI = 1.05-2.5). Conclusion This is the first randomized trial showing that an educational video is superior to printed materials alone when patients are self-consenting for remnant biospecimen donation. This result adds to the evidence that efficient and effective consenting processes can be integrated into clinical workflows to advance universal consenting in medical research.
Collapse
Affiliation(s)
| | - Andrew Kyle
- Division of Internal Medicine at UC Davis, CA, USA
| | | | - Machelle Wilson
- Clinical Translational Science Center, University of California Davis Medical Center, Sacramento, CA, USA
| | - Stephanie Soares
- Clinical Translational Science Center, University of California Davis Medical Center, Sacramento, CA, USA
| |
Collapse
|
8
|
Dewandel I, van Niekerk M, Ghimenton-Walters E, Palmer M, Anthony MG, McKenzie C, Croucamp R, Alter G, Demers AM, van Zyl G, Claassen M, Goussard P, Swanepoel R, Hoddinott G, Bosch C, Dunbar R, Allwood B, McCollum ED, Schaaf HS, Hesseling AC, van der Zalm MM. UMOYA: a prospective longitudinal cohort study to evaluate novel diagnostic tools and to assess long-term impact on lung health in South African children with presumptive pulmonary TB-a study protocol. BMC Pulm Med 2023; 23:97. [PMID: 36949477 PMCID: PMC10032249 DOI: 10.1186/s12890-023-02329-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Accepted: 01/17/2023] [Indexed: 03/24/2023] Open
Abstract
BACKGROUND Despite a high paediatric tuberculosis (TB) burden globally, sensitive and specific diagnostic tools are lacking. In addition, no data exist on the impact of pulmonary TB on long-term child lung health in low- and middle-income countries. The prospective observational UMOYA study aims (1) to build a state-of-the-art clinical, radiological, and biological repository of well-characterised children with presumptive pulmonary TB as a platform for future studies to explore new emerging diagnostic tools and biomarkers for early diagnosis and treatment response; and (2) to investigate the short and long-term impact of pulmonary TB on lung health and quality of life in children. METHODS We will recruit up to 600 children (0-13 years) with presumptive pulmonary TB and 100 healthy controls. Recruitment started in November 2017 and is expected to continue until May 2023. Sputum and non-sputum-based samples are collected at enrolment and during follow-up in TB cases and symptomatic controls. TB treatment is started by routine care services. Intensive follow-up for 6 months will allow for TB cases to retrospectively be classified according to international consensus clinical case definitions for TB. Long-term follow-up, including imaging, comprehensive assessment of lung function and quality of life questionnaires, are done yearly up to 4 years after recruitment. DISCUSSION The UMOYA study will provide a unique platform to evaluate new emerging diagnostic tools and biomarkers for early diagnosis and treatment response and to investigate long-term outcomes of pulmonary TB and other respiratory events on lung health in children.
Collapse
Affiliation(s)
- Isabelle Dewandel
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Margaret van Niekerk
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Elisabetta Ghimenton-Walters
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- Newcastle-Upon-Tyne National Health Service Hospitals Foundation Trust, Newcastle upon Tyne, UK
| | - Megan Palmer
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Michaile G Anthony
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Carla McKenzie
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Rolanda Croucamp
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Galit Alter
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA
- Moderna Therapeutics, Cambridge, MA, USA
| | - Anne-Marie Demers
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- Division of Microbiology, Department of Laboratory Medicine, Centre Hospitalier Universitaire Sainte-Justine, Quebec, Canada
- Department of Microbiology, Immunology and Infectious Diseases, Faculty of Medicine, University of Montreal, Quebec, Canada
| | - Gert van Zyl
- Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- National Health Laboratory Service, Tygerberg Business Unit, Cape Town, South Africa
| | - Mathilda Claassen
- Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Pierre Goussard
- Department of Paediatric Pulmonology, Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa
| | - Ruan Swanepoel
- Department of Pulmonology and Lung Function, Tygerberg Hospital, Cape Town, South Africa
| | - Graeme Hoddinott
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Corne Bosch
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Rory Dunbar
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Brian Allwood
- Department of Pulmonology, Department of Medicine, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
| | - Eric D McCollum
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- Global Program in Pediatric Respiratory Sciences, Eudowood Division of Pediatric Respiratory Sciences, Johns Hopkins School of Medicine, Baltimore, USA
| | - H Simon Schaaf
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Anneke C Hesseling
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Marieke M van der Zalm
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
| |
Collapse
|
9
|
Kuguyo O, Chambwe N, Nhachi CFB, Tsikai N, Dandara C, Matimba A. A cervical cancer biorepository for pharmacogenomics research in Zimbabwe. BMC Cancer 2022; 22:1320. [PMID: 36526993 PMCID: PMC9756582 DOI: 10.1186/s12885-022-10413-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Accepted: 12/06/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Research infrastructures such as biorepositories are essential to facilitate genomics and its growing applications in health research and translational medicine in Africa. Using a cervical cancer cohort, this study describes the establishment of a biorepository consisting of biospecimens and matched phenotype data for use in genomic association analysis and pharmacogenomics research. METHOD Women aged > 18 years with a recent histologically confirmed cervical cancer diagnosis were recruited. A workflow pipeline was developed to collect, store, and analyse biospecimens comprising donor recruitment and informed consent, followed by data and biospecimen collection, nucleic acid extraction, storage of genomic DNA, genetic characterization, data integration, data analysis and data interpretation. The biospecimen and data storage infrastructure included shared -20 °C to -80 °C freezers, lockable cupboards, secured access-controlled laptop, password protected online data storage on OneDrive software. The biospecimen or data storage, transfer and sharing were compliant with the local and international biospecimen and data protection laws and policies, to ensure donor privacy, trust, and benefits for the wider community. RESULTS This initial establishment of the biorepository recruited 410 women with cervical cancer. The mean (± SD) age of the donors was 52 (± 12) years, comprising stage I (15%), stage II (44%), stage III (47%) and stage IV (6%) disease. The biorepository includes whole blood and corresponding genomic DNA from 311 (75.9%) donors, and tumour biospecimens and corresponding tumour DNA from 258 (62.9%) donors. Datasets included information on sociodemographic characteristics, lifestyle, family history, clinical information, and HPV genotype. Treatment response was followed up for 12 months, namely, treatment-induced toxicities, survival vs. mortality, and disease status, that is disease-free survival, progression or relapse, 12 months after therapy commencement. CONCLUSION The current work highlights a framework for developing a cancer genomics cohort-based biorepository on a limited budget. Such a resource plays a central role in advancing genomics research towards the implementation of personalised management of cancer.
Collapse
Affiliation(s)
- Oppah Kuguyo
- grid.13001.330000 0004 0572 0760Clinical Pharmacology Department, University of Zimbabwe College of Health Sciences, Avondale, Mazowe Street, Harare, Zimbabwe
| | - Nyasha Chambwe
- grid.416477.70000 0001 2168 3646Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY USA
| | - Charles F. B. Nhachi
- grid.13001.330000 0004 0572 0760Clinical Pharmacology Department, University of Zimbabwe College of Health Sciences, Avondale, Mazowe Street, Harare, Zimbabwe
| | - Nomsa Tsikai
- grid.13001.330000 0004 0572 0760Department of Oncology, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
| | - Collet Dandara
- grid.7836.a0000 0004 1937 1151Pharmacogenomics and Drug Metabolism Research Group, Division of Human Genetics, Department of Pathology & Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - Alice Matimba
- grid.13001.330000 0004 0572 0760Clinical Pharmacology Department, University of Zimbabwe College of Health Sciences, Avondale, Mazowe Street, Harare, Zimbabwe
| |
Collapse
|
10
|
Kelly RJ, Whitsett TG, Snipes GJ, Dobin SM, Finholt J, Settele N, Priest EL, Youens K, Wallace LB, Schwartz G, Wong L, Henderson SM, Gowan AC, Fonkem E, Juarez MI, Murray CE, Wu J, Van Keuren-Jensen K, Pirrotte P, Highlander S, Contente T, Baker A, Victorino J, Berens ME. The Texas Immuno-Oncology Biorepository, a statewide biospecimen collection and clinical informatics system to enable longitudinal tumor and immune profiling. Proc (Bayl Univ Med Cent) 2022; 36:1-7. [PMID: 36578607 PMCID: PMC9762845 DOI: 10.1080/08998280.2022.2114129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
A detailed understanding of the molecular and immunological changes that occur longitudinally across tumors exposed to immune checkpoint inhibitors is a significant knowledge gap in oncology. To address this unmet need, we created a statewide biospecimen collection and clinical informatics system to enable longitudinal tumor and immune profiling and to enhance translational research. The Texas Immuno-Oncology Biorepository (TIOB) consents patients to collect, process, store, and analyze serial biospecimens of tissue, blood, urine, and stool from a diverse population of over 100,000 cancer patients treated each year across the Baylor Scott & White Health system. Here we sought to demonstrate that these samples were fit for purpose with regard to downstream multi-omic assays. Plasma, urine, peripheral blood mononuclear cells, and stool samples from 11 enrolled patients were collected from various cancer types. RNA isolated from extracellular vesicles derived from plasma and urine was sufficient for transcriptomics. Peripheral blood mononuclear cells demonstrated excellent yield and viability. Ten of 11 stool samples produced RNA quality to enable microbiome characterization. Sample acquisition and processing methods are known to impact sample quality and performance. We demonstrate that consistent acquisition methodology, sample preparation, and sample storage employed by the TIOB can produce high-quality specimens, suited for employment in a wide array of multi-omic platforms, enabling comprehensive immune and molecular profiling.
Collapse
Affiliation(s)
- Ronan J. Kelly
- Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas,Corresponding author: Ronan J. Kelly, MD, MBA, Charles A. Sammons Cancer Center, Baylor University Medical Center, 3420 Worth Street, Suite 550, Dallas, TX75246 (e-mail: ); Michael E. Berens, PhD, Cancer & Cell Biology Division, Translational Genomics Research Institute, 445 N. Fifth Street, Phoenix, AZ85004 (e-mail: )
| | - Timothy G. Whitsett
- Neurogenomics Division, Translational Genomics Research Institute (TGen), Phoenix, Arizona
| | - G. Jackson Snipes
- Department of Pathology, Baylor University Medical Center, Dallas, Texas
| | - Sheila M. Dobin
- Department of Pathology, Baylor Scott & White Medical Center – Temple, Temple, Texas
| | | | | | | | - Kenneth Youens
- Department of Pathology, Baylor University Medical Center, Dallas, Texas
| | - Lucy B. Wallace
- Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas,Texas A&M Health Science Center, Dallas, Texas
| | - Gary Schwartz
- Department of Thoracic Surgery, Baylor University Medical Center, Dallas, Texas
| | - Lucas Wong
- Texas A&M Health Science Center, Dallas, Texas,Department of Hematology and Medical Oncology, Baylor Scott & White Medical Center – Temple, Temple, Texas
| | | | - Alan C. Gowan
- Baylor Scott & White Vasicek Cancer Treatment Center – Temple, Temple, Texas
| | - Ekokobe Fonkem
- Texas A&M Health Science Center, Dallas, Texas,Department of Neurosurgery, Baylor Scott & White Medical Center – Temple, Temple, Texas
| | - Maria I. Juarez
- Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas
| | - Christal E. Murray
- Department of Hematology and Medical Oncology, Baylor Scott & White Medical Center – Temple, Temple, Texas,Baylor Scott & White Cancer Center – Round Rock, Round Rock, Texas
| | - Jeffrey Wu
- Department of Cardiac and Thoracic Surgery, Baylor Scott & White All Saints Medical Center, Fort Worth, Texas
| | | | - Patrick Pirrotte
- Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona
| | - Sarah Highlander
- Pathogen and Microbiome Division, Translational Genomics Research Institute, Phoenix, Arizona
| | - Tania Contente
- Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona
| | - Angela Baker
- Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona
| | - Jose Victorino
- Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona
| | - Michael E. Berens
- Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona,Corresponding author: Ronan J. Kelly, MD, MBA, Charles A. Sammons Cancer Center, Baylor University Medical Center, 3420 Worth Street, Suite 550, Dallas, TX75246 (e-mail: ); Michael E. Berens, PhD, Cancer & Cell Biology Division, Translational Genomics Research Institute, 445 N. Fifth Street, Phoenix, AZ85004 (e-mail: )
| |
Collapse
|
11
|
Sergi CM. Biorepository - A key component of research studies. Contemp Clin Trials 2022; 112:106655. [PMID: 34906746 DOI: 10.1016/j.cct.2021.106655] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Revised: 12/04/2021] [Accepted: 12/08/2021] [Indexed: 01/01/2023]
Abstract
The last two decades have shown impressive advances in high-throughput assays for gene expression (genomics), proteins (proteomics), and metabolites (metabolomics). As a result, the quest for an equivalent need for human biological samples has increased exponentially. Translational investigations require good quality specimens to guarantee research results' integrity, probity, and reproducibility. A biorepository is a bank of specimens or specimens-derived neosamples (e.g., organoids, nucleic acids) linked to a database containing information related to these specimens. Two requirements must be met to safeguard the authenticity and stability of such a repository. First, the information provided should comprise relevant clinical and therapeutic communication, and second, the chain of custody is assured, guarded, versatile, and accessible. Completing these requirements is crucial for consistency, accuracy, verifiability, and disclosability of scientific and clinical outcomes. This commentary emphasizes that advocacy for standardization of operational workflows is a sine qua non for good science. Safe procedures for clinical trials are crucial to maintaining biorepositories' validity for all researchers.
Collapse
|
12
|
Raine-Bennett T, Gage JC, Poitras N, Chandra M, Varnado N, Befano B, Schiffman M, Lorey T, Wentzensen N. Development of a large biorepository of cervical specimens for the Improving Risk Informed HPV Screening study (IRIS). J Clin Virol 2021; 145:105014. [PMID: 34768232 DOI: 10.1016/j.jcv.2021.105014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 10/09/2021] [Accepted: 10/21/2021] [Indexed: 12/27/2022]
Abstract
INTRODUCTION Biomarkers of Human Papillomavirus (HPV) cervical carcinogenesis are critical to address questions of how to triage and manage women who screen positive for high-risk HPV (HrHPV) and identify those at highest cancer risk. METHODS We describe the development of a large biorepository of cervical specimens for the Improving Risk Informed HPV Screening Study (IRIS) using residual specimens collected in the regional laboratory from women aged 25 and older who had cervical cancer screening or follow-up testing with high-risk human papillomavirus (HrHPV) testing and liquid-based cytology (co-testing) at Kaiser Permanente Northern California (KPNC) from January 2016 to August 2018. Specimen selection, processing for long-term storage, follow-up tracking, consent and demographic and clinical characteristics of the women in the IRIS cohort are described. RESULTS Selecting from 897,680 women who had at least one co-test during the study period, we collected 199,403 baseline and 216,390 follow-up HrHPV and cytology specimens from a stratified random sample of 81,348 women, of which 3,428 (4.2%) opted out of the study and were excluded. The majority (79.9%) of the baseline specimens were from HrHPV-positive women. The mean age was 36 years, and the cohort is racially/ethnically diverse with 56% of women being Hispanic or non-white. Over two-thirds of the cohort were members of KPNC for two or more years prior to inclusion. Of the 77,920 women included in the cohort, 57,414 (73.7%) had at least one follow-up co-test. CONCLUSION Use of specimens from the biorepository will elucidate molecular mechanisms underlying HPV carcinogenesis and inform more effective screening and follow-up strategies.
Collapse
Affiliation(s)
- Tina Raine-Bennett
- Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, United States of America; Present affiliation: Medicines360, 353 Sacramento Street, Suite 300, San Francisco, CA, United States of America
| | - Julia C Gage
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, 9609 Medical Center Drive, MSC 9776 Bethesda, MD, United States of America
| | - Nancy Poitras
- Regional Laboratory, Kaiser Permanente Northern California, 1725 Eastshore Hwy, Berkeley, CA, United States of America
| | - Malini Chandra
- Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, United States of America
| | - Nicole Varnado
- Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, United States of America
| | - Brian Befano
- Information Management Services Inc, 3901 Calverton Blvd #200, Calverton, MD, United States of America
| | - Mark Schiffman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, 9609 Medical Center Drive, MSC 9776 Bethesda, MD, United States of America
| | - Thomas Lorey
- Regional Laboratory, Kaiser Permanente Northern California, 1725 Eastshore Hwy, Berkeley, CA, United States of America
| | - Nicolas Wentzensen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, 9609 Medical Center Drive, MSC 9776 Bethesda, MD, United States of America.
| |
Collapse
|
13
|
Bajerski F, Nagel M, Overmann J. Microbial occurrence in liquid nitrogen storage tanks: a challenge for cryobanking? Appl Microbiol Biotechnol 2021; 105:7635-7650. [PMID: 34559283 PMCID: PMC8460408 DOI: 10.1007/s00253-021-11531-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2021] [Revised: 08/13/2021] [Accepted: 08/18/2021] [Indexed: 11/30/2022]
Abstract
Abstract Modern biobanks maintain valuable living materials for medical diagnostics, reproduction medicine, and conservation purposes. To guarantee high quality during long-term storage and to avoid metabolic activities, cryostorage is often conducted in the N2 vapour phase or in liquid nitrogen (LN) at temperatures below − 150 °C. One potential risk of cryostorage is microbial cross contamination in the LN storage tanks. The current review summarises data on the occurrence of microorganisms that may compromise the safety and quality of biological materials during long-term storage. We assess the potential for the microbial contamination of LN in storage tanks holding different biological materials based on the detection by culture-based and molecular approaches. The samples themselves, the LN, the human microbiome, and the surrounding environment are possible routes of contamination and can cause cross contaminations via the LN phase. In general, the results showed that LN is typically not the source of major contaminations and only a few studies provided evidence for a risk of microbial cross contamination. So far, culture-based and culture-independent techniques detected only low amounts of microbial cells, indicating that cross contamination may occur at a very low frequency. To further minimise the potential risk of microbial cross contaminations, we recommend reducing the formation of ice crystals in cryotanks that can entrap environmental microorganisms and using sealed or second sample packing. A short survey demonstrated the awareness for microbial contaminations of storage containers among different culture collections. Although most participants consider the risk of cross contaminations in LN storage tanks as low, they prevent potential contaminations by using sealed devices and − 150 °C freezers. It is concluded that the overall risk for cross contaminations in biobanks is relatively low when following standard operating procedures (SOPs). We evaluated the potential sources in detail and summarised our results in a risk assessment spreadsheet which can be used for the quality management of biobanks. Key points • Identification of potential contaminants and their sources in LN storage tanks. • Recommendations to reduce this risk of LN storage tank contamination. • Development of a risk assessment spreadsheet to support quality management. Supplementary Information The online version contains supplementary material available at 10.1007/s00253-021-11531-4.
Collapse
Affiliation(s)
- Felizitas Bajerski
- Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Inhoffenstraße 7B, 38124, Brunswick, Germany.
| | - Manuela Nagel
- Genebank Department, Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), 06466, Seeland OT Gatersleben, Germany
| | - Joerg Overmann
- Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Inhoffenstraße 7B, 38124, Brunswick, Germany.,Institute of Microbiology, Braunschweig University of Technology, 38106, Brunswick, Germany
| |
Collapse
|
14
|
Schon SB, Raja N, Xu M, Cameron H, Yang K, Reynolds J, Fenner D, Marsh EE. Establishing a reproductive biorepository for basic and translational research: experience developing the reproductive subjects registry and sample repository. J Assist Reprod Genet 2021; 38:2097-2105. [PMID: 33786733 PMCID: PMC8417183 DOI: 10.1007/s10815-021-02165-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 03/21/2021] [Indexed: 11/29/2022] Open
Abstract
PURPOSE To report experience designing and establishing a reproductive registry and sample biorepository and to describe initial subject characteristics and biospecimens. METHODS Beginning in December 2017, patients presenting for reproductive care at the University of Michigan were approached for study enrollment. Following consent, subjects completed detailed reproductive and health questionnaires. A variety of reproductive specimens and tissues were collected and processed for multiple downstream applications. RESULTS Subject enrollment began in December of 2017. There are currently 1798 subjects enrolled. Female participants report a variety of reproductive disorders. Available samples include semen, sperm, follicular fluid, granulosa cells, immature oocytes, ovarian and uterine tissue, and blood samples. CONCLUSION We report the successful establishment of a reproductive registry and sample biorepository. Furthermore, we describe methods for collection and storage of a variety of reproductive tissue processed for multiple downstream translational applications.
Collapse
Affiliation(s)
- Samantha B Schon
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA.
| | - Nicholas Raja
- Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA
| | - Min Xu
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA
| | - Heather Cameron
- Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA
| | - Kun Yang
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA
| | - Jayne Reynolds
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA
| | - Dee Fenner
- Division of Female Pelvic Medicine & Reconstructive Surgery, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA
| | - Erica E Marsh
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA
| |
Collapse
|
15
|
LaVergne SM, Stromberg S, Baxter BA, Webb TL, Dutt TS, Berry K, Tipton M, Haberman J, Massey BR, McFann K, Alnachoukati O, Zier L, Heacock T, Ebel GD, Henao-Tamayo M, Dunn J, Ryan EP. A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae. BMC Infect Dis 2021; 21:677. [PMID: 34256735 PMCID: PMC8276222 DOI: 10.1186/s12879-021-06359-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Accepted: 06/25/2021] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND SARS-CoV-2 has swept across the globe, causing millions of deaths worldwide. Though most survive, many experience symptoms of COVID-19 for months after acute infection. Successful prevention and treatment of acute COVID-19 infection and its associated sequelae is dependent on in-depth knowledge of viral pathology across the spectrum of patient phenotypes and physiologic responses. Longitudinal biobanking provides a valuable resource of clinically integrated, easily accessed, and quality-controlled samples for researchers to study differential multi-organ system responses to SARS-CoV-2 infection, post-acute sequelae of COVID-19 (PASC), and vaccination. METHODS Adults with a history of a positive SARS-CoV-2 nasopharyngeal PCR are actively recruited from the community or hospital settings to enroll in the Northern Colorado SARS-CoV-2 Biorepository (NoCo-COBIO). Blood, saliva, stool, nasopharyngeal specimens, and extensive clinical and demographic data are collected at 4 time points over 6 months. Patients are assessed for PASC during longitudinal follow-up by physician led symptom questionnaires and physical exams. This clinical trial registration is NCT04603677 . RESULTS We have enrolled and collected samples from 119 adults since July 2020, with 66% follow-up rate. Forty-nine percent of participants assessed with a symptom surveillance questionnaire (N = 37 of 75) had PASC at any time during follow-up (up to 8 months post infection). Ninety-three percent of hospitalized participants developed PASC, while 23% of those not requiring hospitalization developed PASC. At 90-174 days post SARS-CoV-2 diagnosis, 67% of all participants had persistent symptoms (N = 37 of 55), and 85% percent of participants who required hospitalization during initial infection (N = 20) still had symptoms. The most common symptoms reported after 15 days of infection were fatigue, loss of smell, loss of taste, exercise intolerance, and cognitive dysfunction. CONCLUSIONS Patients who were hospitalized for COVID-19 were significantly more likely to have PASC than those not requiring hospitalization, however 23% of patients who were not hospitalized also developed PASC. This patient-matched, multi-matrix, longitudinal biorepository from COVID-19 survivors with and without PASC will allow for current and future research to better understand the pathophysiology of disease and to identify targeted interventions to reduce risk for PASC. Registered 27 October 2020 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04603677 .
Collapse
Affiliation(s)
- Stephanie M LaVergne
- Department of Environmental and Radiological Health Sciences, Colorado State University, 1601 Campus Delivery, Fort Collins, CO, 80523, USA
| | - Sophia Stromberg
- Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, CO, USA
| | - Bridget A Baxter
- Department of Environmental and Radiological Health Sciences, Colorado State University, 1601 Campus Delivery, Fort Collins, CO, 80523, USA
| | - Tracy L Webb
- Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA
| | - Taru S Dutt
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA
| | - Kailey Berry
- Department of Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
| | - Madison Tipton
- Department of Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
| | - Jared Haberman
- Department of Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
| | | | - Kim McFann
- University of Colorado Health, Medical Center of the Rockies, Loveland, CO, USA
| | - Omar Alnachoukati
- University of Colorado Health, Medical Center of the Rockies, Loveland, CO, USA
| | - Linda Zier
- University of Colorado Health, Medical Center of the Rockies, Loveland, CO, USA
| | - Thomas Heacock
- University of Colorado Health, Medical Center of the Rockies, Loveland, CO, USA
| | - Gregory D Ebel
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA
| | - Marcela Henao-Tamayo
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA
| | - Julie Dunn
- University of Colorado Health, Medical Center of the Rockies, Loveland, CO, USA
| | - Elizabeth P Ryan
- Department of Environmental and Radiological Health Sciences, Colorado State University, 1601 Campus Delivery, Fort Collins, CO, 80523, USA.
| |
Collapse
|
16
|
Prudent J, Lopez E, Dorshorst D, Cox HC, Bodurtha JN. Demographic and socioeconomic trends in DNA banking utilization in the USA. J Community Genet 2021; 12:593-602. [PMID: 34185264 PMCID: PMC8239484 DOI: 10.1007/s12687-021-00533-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 05/24/2021] [Indexed: 12/28/2022] Open
Abstract
Demographic and clinical information from de-identified individuals utilizing a single DNA banking service over a 22-year period was assessed using descriptive statistics. The socioeconomic characteristics of the study population were estimated using a zip code–level analysis of US Census data and compared to national US Metrics for 2016. Samples from 4,874 individuals were deposited to a single commercial DNA bank from 1997 to 2019. Samples originated from 31 countries across 6 continents, with the majority of samples originating from the United States (US; 97.37%; n = 4,746). A higher proportion of individuals identifying as females (55.58%; n = 2,709) utilized the service compared to males (41.18%; n = 2,007). The age distribution was bimodal, peaking around 5 years of age and again around 65 years of age. Whole blood was the preferred specimen for submission. Sample deposits peaked in 2015 with 559 annual deposits. Clinical genetic counselors were the most common referral source (41.73%; n = 2,034). Individuals utilizing DNA banking services are estimated to reside in wealthier, more educated and less racially diverse zip codes compared to national metrics. Although direct to consumer DNA banking is being utilized by the general public and clinical genetic counselors in the US, it is not widespread.
Collapse
Affiliation(s)
- Joshua Prudent
- Department of Genetic Medicine, Johns Hopkins School of Medicine, 600 N. Wolfe St., Blalock 1012, Baltimore, MD, 21287, USA
| | - Esthermarie Lopez
- Ponce Health Sciences University, 388 Zona Industrial Reparada 2, Ponce, PR, 00716, Puerto Rico
| | - Donna Dorshorst
- Prevention Genetics LLC, 3800 S. Business Park Avenue, WI, 54,449, Marshfield, USA
| | - Hannah C Cox
- Prevention Genetics LLC, 3800 S. Business Park Avenue, WI, 54,449, Marshfield, USA.
| | - Joann N Bodurtha
- Department of Genetic Medicine, Johns Hopkins School of Medicine, 600 N. Wolfe St., Blalock 1012, Baltimore, MD, 21287, USA.
| |
Collapse
|
17
|
Wagner H, Kenk M, Fraser M, Berlin A, Fleshner N. Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. Eur Urol Focus 2021; 7:513-521. [PMID: 34167926 DOI: 10.1016/j.euf.2021.06.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 05/15/2021] [Accepted: 06/04/2021] [Indexed: 11/27/2022]
Abstract
CONTEXT Translational research in uro-oncology depends on the availability of high-quality biospecimens and associated data to advance precision medicine and improve clinical outcomes. Procurement, storage, and annotation of these specimens represent critical steps towards this end. OBJECTIVE To review best-practice experiences gained via the McCain GU BioBank, a repository of more than 750 000 biospecimens obtained from more than 16 000 patients attending clinics at the University Health Network in Toronto, Canada. EVIDENCE ACQUISITION The review summarizes our experiences at a large single-institution genitourinary oncology biorepository. EVIDENCE SYNTHESIS Key findings are placed in the context of emerging trends in genitourinary oncology, with a focus on integration of molecular profiling and clinical data with traditional biorepository management. Proposed approaches provide high-quality biospecimens with comprehensive and reliable clinical data that can fuel innovation and discovery in research. CONCLUSIONS Biorepositories are vital for improving clinical outcomes and advancing personalized medicine. High-quality biospecimens and their associated clinical data are crucial for validation of biomarkers in oncology. Efforts to procure, store, and annotate clinical specimens represent critical steps in translational research. Elements such as biobank size, biospecimen types, disease cohorts, predetermined collection protocols, broad informed consent, sample handling and storage protocols, and available infrastructure directly influence the effectiveness and capacity of a biobank. PATIENT SUMMARY Biorepositories, or biobanks, are facilities that store biospecimens such as blood, urine, or tissue (usually collected from humans) for use in research. Biobanks have become an important resource in medical research, as they provide high-quality specimens to support different types of contemporary research such as genomics, biomarker discovery, and personalized medicine. Clinical management and treatment of genitourinary cancers, such as prostate, kidney, and bladder cancers, are particularly suited for biomarker research. The provision of biospecimens and their associated clinical data have become crucial for validation of biomarkers in these cancers.
Collapse
Affiliation(s)
- Heidi Wagner
- McCain GU BioBank, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
| | - Miran Kenk
- McCain GU BioBank, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Michael Fraser
- McCain GU BioBank, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Faculty of Medicine, University of Toronto, Toronto, Canada; Canadian Prostate Cancer Genome Network, Toronto, Canada
| | - Alejandro Berlin
- Faculty of Medicine, University of Toronto, Toronto, Canada; Canadian Prostate Cancer Genome Network, Toronto, Canada; Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Neil Fleshner
- McCain GU BioBank, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Faculty of Medicine, University of Toronto, Toronto, Canada
| |
Collapse
|
18
|
Chróścicka A, Paluch A, Kozera Ł, Lewandowska-Szumieł M. The landscape of biobanks in Poland-characteristics of Polish biobanking units at the beginning of BBMRI.pl organization. J Transl Med 2021; 19:267. [PMID: 34158056 DOI: 10.1186/s12967-021-02926-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 06/04/2021] [Indexed: 12/01/2022] Open
Abstract
Background Biobanking is an area of scientific activity that is growing in strength and importance. The variety of collections combining biological samples and medical scientific information makes biobanking an indispensable tool in the development of modern medicine. In 2016, Poland, a country with one of the largest populations in Europe, joined the Biobanking and BioMolecular resources Research Infrastructure-European Research Infrastructure Consortium (BBMRI-ERIC) to facilitate access to quality-defined human disease-relevant biological resources. This push led to the development of the Polish Biobanking Network. The purpose of this paper is to present the current state of biobanks in Poland in the context of their location, nature and resources. Methods To obtain information about and overall characteristics of Polish entities dealing with biobanking biological material, the dedicated Information Survey was designed. The survey was prepared in an electronic form and consisted of 53 questions—both open and closed, single and multiple choice—with some questions depending on each other. Sixty-five Polish biobanks/biorepositories participated in the survey. Results Polish biobanks are mostly affiliated with research entities (universities—42% and research institutes—30%). The data collected indicate that a considerable number of Polish biobanks are specialized (33 units), in contrast to population-based biobanks (8 units). These biobanks are mostly focused on collecting samples from oncological (23 biobanks) and rare diseases (12 biobanks). In general, great diversity was found in the material collected. Scientists working in Polish biobanks are very open to scientific cooperation (declared by 60% of units) and sharing their collections with the international scientific environment. In terms of quality issues, most biobanks declared that their quality management system was in the process of implementation (45%) or had already been implemented (23%). Conclusions Although biobanking in Poland is still in its infancy, the results of this study seem promising and may be valuable to the wider biobanking research community. The distribution of biobanks throughout the Polish territory, their connection with scientific and clinical units, and their involvement in research on rare diseases may contribute to an increase in the number of multicenter studies.
Collapse
|
19
|
Croker JA, Patel R, Campbell KS, Barton-Baxter M, Wallet S, Firestein GS, Kimberly RP, Elemento O. Building biorepositories in the midst of a pandemic. J Clin Transl Sci 2021; 5:e92. [PMID: 34192049 PMCID: PMC8134891 DOI: 10.1017/cts.2021.6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 01/21/2021] [Accepted: 01/22/2021] [Indexed: 11/07/2022] Open
Abstract
Biospecimen repositories play a vital role in enabling investigation of biologic mechanisms, identification of disease-related biomarkers, advances in diagnostic assays, recognition of microbial evolution, and characterization of new therapeutic targets for intervention. They rely on the complex integration of scientific need, regulatory oversight, quality control in collection, processing and tracking, and linkage to robust phenotype information. The COVID-19 pandemic amplified many of these considerations and illuminated new challenges, all while academic health centers were trying to adapt to unprecedented clinical demands and heightened research constraints not witnessed in over 100 years. The outbreak demanded rapid understanding of SARS-CoV-2 to develop diagnostics and therapeutics, prompting the immediate need for access to high quality, well-characterized COVID-19-associated biospecimens. We surveyed 60 Clinical and Translational Science Award (CTSA) hubs to better understand the strategies and barriers encountered in biobanking before and in response to the COVID-19 pandemic. Feedback revealed a major shift in biorepository model, specimen-acquisition and consent process from a combination of investigator-initiated and institutional protocols to an enterprise-serving strategy. CTSA hubs were well equipped to leverage established capacities and expertise to quickly respond to the scientific needs of this crisis through support of institutional approaches in biorepository management.
Collapse
Affiliation(s)
- Jennifer A. Croker
- Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Robin Patel
- Division of Clinical Microbiology, Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA
| | - Kenneth S. Campbell
- Center for Clinical and Translational Science, University of Kentucky, Lexington, KY, USA
| | - Marietta Barton-Baxter
- Center for Clinical and Translational Science, University of Kentucky, Lexington, KY, USA
| | - Shannon Wallet
- North Carolina Translational and Clinical Sciences Institute, University of North Carolina, Chapel Hill, NC, USA
| | - Gary S. Firestein
- Altman Clinical & Translational Science Institute, University of California San Diego, San Diego, CA, USA
| | - Robert P. Kimberly
- Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Olivier Elemento
- Clinical & Translational Science Center, Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA
| |
Collapse
|
20
|
Lima R, Gootkind EF, De la Flor D, Yockey LJ, Bordt EA, D'Avino P, Ning S, Heath K, Harding K, Zois J, Park G, Hardcastle M, Grinke KA, Grimmel S, Davidson SP, Forde PJ, Hall KE, Neilan AM, Matute JD, Lerou PH, Fasano A, Shui JE, Edlow AG, Yonker LM. Establishment of a pediatric COVID-19 biorepository: unique considerations and opportunities for studying the impact of the COVID-19 pandemic on children. BMC Med Res Methodol 2020; 20:228. [PMID: 32917141 PMCID: PMC7483494 DOI: 10.1186/s12874-020-01110-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Accepted: 08/30/2020] [Indexed: 01/08/2023] Open
Abstract
Background COVID-19, the disease caused by the highly infectious and transmissible coronavirus SARS-CoV-2, has quickly become a morbid global pandemic. Although the impact of SARS-CoV-2 infection in children is less clinically apparent, collecting high-quality biospecimens from infants, children, and adolescents in a standardized manner during the COVID-19 pandemic is essential to establish a biologic understanding of the disease in the pediatric population. This biorepository enables pediatric centers world-wide to collect samples uniformly to drive forward our understanding of COVID-19 by addressing specific pediatric and neonatal COVID-19-related questions. Methods A COVID-19 biospecimen collection study was implemented with strategic enrollment guidelines to include patients seen in urgent care clinics and hospital settings, neonates born to SARS-CoV-2 infected mothers, and asymptomatic children. The methodology described here, details the importance of establishing collaborations between the clinical and research teams to harmonize protocols for patient recruitment and sample collection, processing and storage. It also details modifications required for biobanking during a surge of the COVID-19 pandemic. Results Considerations and challenges facing enrollment of neonatal and pediatric cohorts are described. A roadmap is laid out for successful collection, processing, storage and database management of multiple pediatric samples such as blood, nasopharyngeal and oropharyngeal swabs, sputum, saliva, tracheal aspirates, stool, and urine. Using this methodology, we enrolled 327 participants, who provided a total of 972 biospecimens. Conclusions Pediatric biospecimens will be key in answering questions relating to viral transmission by children, differences between pediatric and adult viral susceptibility and immune responses, the impact of maternal SARS-CoV-2 infection on fetal development, and factors driving the Multisystem Inflammatory Syndrome in Children. The specimens in this biorepository will allow necessary comparative studies between children and adults, help determine the accuracy of current pediatric viral testing techniques, in addition to, understanding neonatal exposure to SARS-CoV-2 infection and disease abnormalities. The successful establishment of a pediatric biorepository is critical to provide insight into disease pathogenesis, and subsequently, develop future treatment and vaccination strategies.
Collapse
Affiliation(s)
- Rosiane Lima
- Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.,Department of Pediatrics, Division of Gastroenterology and Nutrition, Massachusetts General Hospital, Boston, MA, USA
| | - Elizabeth F Gootkind
- Department of Pediatrics, Pulmonary Division, Massachusetts General Hospital, Boston, MA, USA
| | - Denis De la Flor
- Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Laura J Yockey
- Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.,Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Evan A Bordt
- Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Boston, MA, USA
| | - Paolo D'Avino
- Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Shen Ning
- Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
| | - Katerina Heath
- Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Katherine Harding
- Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Jaclyn Zois
- Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Grace Park
- Department of Pediatrics, Pulmonary Division, Massachusetts General Hospital, Boston, MA, USA
| | - Margot Hardcastle
- Department of Pediatrics, Pulmonary Division, Massachusetts General Hospital, Boston, MA, USA
| | - Kathleen A Grinke
- Translational and Clinical Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Sheila Grimmel
- Translational and Clinical Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Susan P Davidson
- Translational and Clinical Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Pamela J Forde
- Translational and Clinical Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Kathryn E Hall
- Translational and Clinical Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Anne M Neilan
- Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.,Department of Pediatrics, Infectious Disease, Massachusetts General Hospital, Boston, MA, USA
| | - Juan D Matute
- Department of Pediatrics, Division of Neonatology and Newborn Medicine, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Paul H Lerou
- Department of Pediatrics, Division of Neonatology and Newborn Medicine, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Alessio Fasano
- Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.,Department of Pediatrics, Division of Gastroenterology and Nutrition, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Jessica E Shui
- Department of Pediatrics, Infectious Disease, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Andrea G Edlow
- Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Lael M Yonker
- Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA. .,Department of Pediatrics, Pulmonary Division, Massachusetts General Hospital, Boston, MA, USA. .,Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
21
|
Lima R, Gootkind E, De La Flor D, Yockey L, Bordt E, D’Avino P, Ning S, Heath K, Harding K, Zois J, Park G, Hardcastle M, Grinke KA, Grimmel S, Forde PJ, Davidson SP, Hall KE, Neilan A, Matute JD, Lerou PH, Fasano A, Shui JE, Edlow AG, Yonker LM. Establishment of a Pediatric COVID-19 Biorepository: Unique Considerations and Opportunities for Studying the Impact of the COVID-19 Pandemic on Children. Res Sq 2020:rs.3.rs-42030. [PMID: 32818214 PMCID: PMC7430592 DOI: 10.21203/rs.3.rs-42030/v1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Background COVID-19, the disease caused by the highly infectious and transmissible coronavirus SARS-CoV-2, has quickly become a morbid global pandemic. Although the impact of SARS-CoV-2 infection in children is less clinically apparent, collecting high-quality biospecimens from infants, children, and adolescents in a standardized manner during the COVID-19 pandemic is essential to establish a biologic understanding of the disease in the pediatric population. This biorepository enables pediatric centers world-wide to collect samples uniformly to drive forward our understanding of COVID-19 by addressing specific pediatric and neonatal COVID-19-related questions. Methods A COVID-19 biospecimen collection study was implemented with strategic enrollment guidelines to include patients seen in urgent care clinics and hospital settings, neonates born to SARS-CoV-2 infected mothers, and asymptomatic children. The methodology described here, details the importance of establishing collaborations between the clinical and research teams to harmonize protocols for patient recruitment and sample collection, processing and storage. It also details modifications required for biobanking during a surge of the COVID-19 pandemic. Results Considerations and challenges facing enrollment of neonatal and pediatric cohorts are described. A roadmap is laid out for successful collection, processing, storage and database management of multiple pediatric samples such as blood, nasopharyngeal and oropharyngeal swabs, sputum, saliva, tracheal aspirates, stool, and urine. Using this methodology, we enrolled 327 participants, who provided a total of 972 biospecimens. Conclusions Pediatric biospecimens will be key in answering questions relating to viral transmission by children, differences between pediatric and adult viral susceptibility and immune responses, the impact of maternal SARS-CoV-2 infection on fetal development, and factors driving the Multisystem Inflammatory Syndrome in Children. The specimens in this biorepository will allow necessary comparative studies between children and adults, help determine the accuracy of current pediatric viral testing techniques, in addition to, understanding neonatal exposure to SARS-CoV-2 infection and disease abnormalities. The successful establishment of a pediatric biorepository is critical to provide insight into disease pathogenesis, and subsequently, develop future treatment and vaccination strategies.
Collapse
|
22
|
Abstract
BACKGROUND Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease that primarily affects premature infants. Despite medical advances, mortality and morbidity from NEC are still unacceptably high. This is partly because of the lack of specific biomarkers and therapies for this disease. Availability of high-quality biological samples and the associated data from premature infants are key to advance our understanding of NEC, and for biomarker discovery and drug development. To that end, the NEC Society Biorepository was established with the goal of promoting studies in human infants through sharing specialized biospecimen and data procurement for NEC research. OBJECTIVE In this review, we will discuss the required infrastructure for biobanks, discuss the importance of informatics management, and emphasize the logistical requirements for sharing specimens. Finally, we will discuss the mechanism for how tissues and material will be shared between the institutions. CONCLUSION We have developed a state-of-the-art biobank for human infants to advance the field of NEC research. With the NEC Society Biorepository, we seek to facilitate and accelerate the basic and translational studies on NEC to provide hope to the infants afflicted with NEC and their families. STUDY TYPE Review article, level V.
Collapse
MESH Headings
- Biomarkers/metabolism
- Biomedical Research
- Enterocolitis, Necrotizing/diagnosis
- Enterocolitis, Necrotizing/metabolism
- Enterocolitis, Necrotizing/pathology
- Enterocolitis, Necrotizing/therapy
- Humans
- Infant
- Infant, Newborn
- Infant, Premature
- Infant, Premature, Diseases/diagnosis
- Infant, Premature, Diseases/metabolism
- Infant, Premature, Diseases/pathology
- Infant, Premature, Diseases/therapy
- Informatics
- Reference Standards
- Specimen Handling/ethics
- Specimen Handling/methods
- Specimen Handling/standards
- Tissue Banks/ethics
- Tissue Banks/organization & administration
Collapse
Affiliation(s)
- Hala Chaaban
- Department of Pediatrics, Section of Neonatal-Perinatal Medicine, University of Oklahoma, Oklahoma City, OK, USA
| | - Troy A Markel
- Department of Surgery, Section of Pediatric Surgery, The Indiana University School of Medicine, Indianapolis, IN, USA
| | | | - Misty Good
- Department of Pediatrics, Division of Newborn Medicine, Washington University School of Medicine, St. Louis, MO, USA.
| |
Collapse
|
23
|
Meagher KM, Curtis SH, Gamm KO, Sutton EJ, McCormick JB, Sharp RR. At a Moment's Notice: Community Advisory Board Perspectives on Biobank Communication to Supplement Broad Consent. Public Health Genomics 2020; 23:77-89. [PMID: 32396907 DOI: 10.1159/000507057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Accepted: 03/05/2020] [Indexed: 11/19/2022] Open
Abstract
INTRODUCTION To address ethical concerns about the of future research authorization, biobanks employing a broad model of consent can design ongoing communication with contributors. Notifying contributors at the time of sample distribution provides one form of communication to supplement broad consent. However, little is known about how community-informed governance might anticipate contributor responses and inform communication efforts. OBJECTIVE We explored the attitudes of members of a three-site Community Advisory Board (CAB) network. CAB members responded to a hypothetical proposal for notifying biobank contributors at the time of sample distribution to researchers utilizing the biobank. METHODS We used regularly scheduled CAB meetings to facilitate 3 large-group and 6 small-group discussions. Discussions were audio-recorded, transcribed, and analyzed for thematic content using descriptive thematic analysis. RESULTS The results challenged our expectation of general support for the proposed communications. While CAB members identified some advantages, they were concerned about several potential harms to biobank contributors and the biobank. The CABs understood biobank communication in terms of an ongoing relationship with the biobank and a personal contribution to research. CONCLUSION Our findings contribute to the emerging literature on community engagement in biobanking. Additional communication with biobank contributors can serve a variety of value-based objectives to supplement broad consent. Design of communication efforts by biobanks can be improved by CAB members' anticipation of the unintended consequences of additional contact with contributors. CAB members' holistic interpretation of communication efforts suggests that biobank leadership considers all communication options as part of a more comprehensive communications strategy.
Collapse
Affiliation(s)
- Karen M Meagher
- Mayo Clinic Biomedical Ethics Research Program, Rochester, Minnesota, USA
| | - Susan H Curtis
- Mayo Clinic Biomedical Ethics Research Program, Rochester, Minnesota, USA
| | - Kylie O Gamm
- Mayo Clinic Biomedical Ethics Research Program, Rochester, Minnesota, USA
| | - Erica J Sutton
- Mayo Clinic Biomedical Ethics Research Program, Rochester, Minnesota, USA
| | - Jennifer B McCormick
- Department of Humanities, College of Medicine, Pennsylvania State University, Hershey, Pennsylvania, USA
| | - Richard R Sharp
- Mayo Clinic Biomedical Ethics Research Program, Rochester, Minnesota, USA,
| |
Collapse
|
24
|
Craik R, Russell D, Tribe RM, Poston L, Omuse G, Okiro P, Chege D, Diatta M, Sesay AK, Cuamba I, Carrilho C, Sevene E, Flint-O’Kane M, von Dadelszen P. PRECISE pregnancy cohort: challenges and strategies in setting up a biorepository in sub-Saharan Africa. Reprod Health 2020; 17:54. [PMID: 32354368 PMCID: PMC7191687 DOI: 10.1186/s12978-020-0874-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND AND OBJECTIVE PRECISE is a population-based, prospective pregnancy cohort study designed for deep phenotyping of pregnancies in women with placenta-related disorders, and in healthy controls. The PRECISE Network is recruiting ~ 10,000 pregnant women in three countries (The Gambia, Kenya, and Mozambique) representing sub-Saharan Africa. The principal aim is to improve our understanding of pre-eclampsia, fetal growth restriction and stillbirth. This involves the creation of a highly curated biorepository for state of the art discovery science and a rich database of antenatal variables and maternal and neonatal outcomes. Our overarching aim is to provide large sample numbers with adequate power to address key scientific questions. Here we describe our experience of establishing a biorepository in the PRECISE Network and review the issues and challenges surrounding set-up, management and scientific use. METHODS The feasibility of collecting and processing each sample type was assessed in each setting and plans made for establishing the necessary infrastructure. Quality control (QC) protocols were established to ensure that biological samples are 'fit-for-purpose'. The management structures required for standardised sample collection and processing were developed. This included the need for transport of samples between participating countries and to external academic/commercial institutions. RESULTS Numerous practical challenges were encountered in setting up the infrastructure including facilities, staffing, training, cultural barriers, procurement, shipping and sample storage. Whilst delaying the project, these were overcome by establishing good communication with the sites, training workshops and constant engagement with the necessary commercial suppliers. A Project Executive Committee and Biology Working Group together defined the biospecimens required to answer the research questions paying particular attention to harmonisation of protocols with other cohorts so as to enable cross-biorepository collaboration. Governance structures implemented include a Data and Sample Committee to ensure biospecimens and data will be used according to consent, and prioritisation by scientific excellence. A coordinated sample and data transfer agreement will prevent delay in sample sharing. DISCUSSION With adequate training and infrastructure, it is possible to establish high quality sample collections to facilitate research programmes such as the PRECISE Network in sub-Saharan Africa. These preparations are pre-requisites for effective execution of a biomarker-based approach to better understand the complexities of placental disease in these settings, and others.
Collapse
Affiliation(s)
- Rachel Craik
- Department of Women and Children’s Health, School of Life Course Sciences, King’s College London, London, UK
- Nuffield Department of Women’s and Reproductive Health, University of Oxford, Oxford, UK
| | | | - Rachel M. Tribe
- Department of Women and Children’s Health, School of Life Course Sciences, King’s College London, London, UK
| | - Lucilla Poston
- Department of Women and Children’s Health, School of Life Course Sciences, King’s College London, London, UK
| | - Geoffrey Omuse
- Department of Pathology, Aga Khan University Hospital, Nairobi, Kenya
| | - Patricia Okiro
- Department of Pathology, Aga Khan University Hospital, Nairobi, Kenya
| | - David Chege
- Department of Pathology, Aga Khan University Hospital, Nairobi, Kenya
| | - Mathurin Diatta
- Medical Research Council Unit (The Gambia) at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia
| | - Abdul Karim Sesay
- Medical Research Council Unit (The Gambia) at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia
| | | | - Carla Carrilho
- Department of Pathology, Maputo Central Hospital, Maputo, Mozambique
- Department of Physiological Science, Clinical - Pharmacology, Faculty of Medicine, Universidade Eduardo Mondlane, Maputo, Mozambique
| | - Esperança Sevene
- Centro de Investigacão em Saúde de Manhiça, Maputo, Mozambique
- Department of Physiological Science, Clinical - Pharmacology, Faculty of Medicine, Universidade Eduardo Mondlane, Maputo, Mozambique
| | - Meriel Flint-O’Kane
- Department of Women and Children’s Health, School of Life Course Sciences, King’s College London, London, UK
- Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK
| | - Peter von Dadelszen
- Department of Women and Children’s Health, School of Life Course Sciences, King’s College London, London, UK
| |
Collapse
|
25
|
von Dadelszen P, Flint-O'Kane M, Poston L, Craik R, Russell D, Tribe RM, d'Alessandro U, Roca A, Jah H, Temmerman M, Koech Etyang A, Sevene E, Chin P, Lawn JE, Blencowe H, Sandall J, Salisbury TT, Barratt B, Shennan AH, Makanga PT, Magee LA. The PRECISE (PREgnancy Care Integrating translational Science, Everywhere) Network's first protocol: deep phenotyping in three sub-Saharan African countries. Reprod Health 2020; 17:51. [PMID: 32354357 PMCID: PMC7191688 DOI: 10.1186/s12978-020-0872-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND The PRECISE (PREgnancy Care Integrating translational Science, Everywhere) Network is a new and broadly-based group of research scientists and health advocates based in the UK, Africa and North America. METHODS This paper describes the protocol that underpins the clinical research activity of the Network, so that the investigators, and broader global health community, can have access to 'deep phenotyping' (social determinants of health, demographic and clinical parameters, placental biology and agnostic discovery biology) of women as they advance through pregnancy to the end of the puerperium, whether those pregnancies have normal outcomes or are complicated by one/more of the placental disorders of pregnancy (pregnancy hypertension, fetal growth restriction and stillbirth). Our clinical sites are in The Gambia (Farafenni), Kenya (Kilifi County), and Mozambique (Maputo Province). In each country, 50 non-pregnant women of reproductive age will be recruited each month for 1 year, to provide a final national sample size of 600; these women will provide culturally-, ethnically-, seasonally- and spatially-relevant control data with which to compare women with normal and complicated pregnancies. Between the three countries we will recruit ≈10,000 unselected pregnant women over 2 years. An estimated 1500 women will experience one/more placental complications over the same epoch. Importantly, as we will have accurate gestational age dating using the TraCer device, we will be able to discriminate between fetal growth restriction and preterm birth. Recruitment and follow-up will be primarily facility-based and will include women booking for antenatal care, subsequent visits in the third trimester, at time-of-disease, when relevant, during/immediately after birth and 6 weeks after birth. CONCLUSIONS To accelerate progress towards the women's and children's health-relevant Sustainable Development Goals, we need to understand how a variety of social, chronic disease, biomarker and pregnancy-specific determinants health interact to result in either a resilient or a compromised pregnancy for either mother or fetus/newborn, or both. This protocol has been designed to create such a depth of understanding. We are seeking funding to maintain the cohort to better understand the implications of pregnancy complications for both maternal and child health.
Collapse
Affiliation(s)
- Peter von Dadelszen
- Department of Women and Children's Health, School of Life Course Science, Faculty of Life Sciences and Medicine, King's College London, 5th Floor, Becket House, 1 Lambeth Palace Road, London, SE1 7EU, UK.
| | - Meriel Flint-O'Kane
- Department of Women and Children's Health, School of Life Course Science, Faculty of Life Sciences and Medicine, King's College London, 5th Floor, Becket House, 1 Lambeth Palace Road, London, SE1 7EU, UK
| | - Lucilla Poston
- Department of Women and Children's Health, School of Life Course Science, Faculty of Life Sciences and Medicine, King's College London, 5th Floor, Becket House, 1 Lambeth Palace Road, London, SE1 7EU, UK
| | - Rachel Craik
- Department of Women and Children's Health, School of Life Course Science, Faculty of Life Sciences and Medicine, King's College London, 5th Floor, Becket House, 1 Lambeth Palace Road, London, SE1 7EU, UK
- Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK
| | | | - Rachel M Tribe
- Department of Women and Children's Health, School of Life Course Science, Faculty of Life Sciences and Medicine, King's College London, 5th Floor, Becket House, 1 Lambeth Palace Road, London, SE1 7EU, UK
| | - Umberto d'Alessandro
- Medical Research Council Unit (The Gambia) at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia
| | - Anna Roca
- Medical Research Council Unit (The Gambia) at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia
| | - Hawanatu Jah
- Medical Research Council Unit (The Gambia) at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia
| | - Marleen Temmerman
- Centre of Excellence in Women and Child Health, East Africa, Aga Khan University in East Africa, Nairobi, Kenya
| | - Angela Koech Etyang
- Centre of Excellence in Women and Child Health, East Africa, Aga Khan University in East Africa, Nairobi, Kenya
| | - Esperança Sevene
- Centro de Investigação em Saúde de Manhiça, Manhiça, Maputo Province, Mozambique
- Department of Physiological Science, Clinical - Pharmacology, Faculty of Medicine, Universidade Eduardo Mondlane, Maputo, Mozambique
| | - Paulo Chin
- Centro de Investigação em Saúde de Manhiça, Manhiça, Maputo Province, Mozambique
| | - Joy E Lawn
- MARCH Centre, London School of Hygiene and Tropical Medicine, London, UK
| | - Hannah Blencowe
- MARCH Centre, London School of Hygiene and Tropical Medicine, London, UK
| | - Jane Sandall
- Department of Women and Children's Health, School of Life Course Science, Faculty of Life Sciences and Medicine, King's College London, 5th Floor, Becket House, 1 Lambeth Palace Road, London, SE1 7EU, UK
| | - Tatiana T Salisbury
- Department of Health Service and Population Research, Institute of Psychiatry, King's College London, London, UK
| | - Benjamin Barratt
- Lau China Institute, Faculty of Social Science and Public Policy, King's College London, London, UK
| | - Andrew H Shennan
- Department of Women and Children's Health, School of Life Course Science, Faculty of Life Sciences and Medicine, King's College London, 5th Floor, Becket House, 1 Lambeth Palace Road, London, SE1 7EU, UK
| | | | - Laura A Magee
- Department of Women and Children's Health, School of Life Course Science, Faculty of Life Sciences and Medicine, King's College London, 5th Floor, Becket House, 1 Lambeth Palace Road, London, SE1 7EU, UK
| |
Collapse
|
26
|
Zhuntova G, Loffredo C, Grigoryeva E, Sychugov G, Kazachkov E, Kirillova E, Azizova T. The Russian Radiobiological Human Tissue Repository: characteristics of biological specimens donated by nuclear workers with lung cancer. Int J Radiat Biol 2020; 96:577-583. [PMID: 31976795 DOI: 10.1080/09553002.2020.1721596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Purpose: Characteristics of biological specimens donated by nuclear workers with lung cancer.Materials and methods: Biological specimens were identified at the Radiobiological Human Tissue Repository (RHTR). It was established at the Southern Urals Biophysics Institute in Russia and has been developed and supported within the bilateral US-Russian Agreement on International Cooperation for Minimization of the Effects of Prolonged Radiation Exposure. Biological specimens were collected from workers of the Russian nuclear production facility Mayak PA who were exposed to gamma radiation and/or alpha particles. To determine a histologic type of lung cancer, immunohistochemistry was used.Results and conclusions: Today biological specimens donated by 343 registrants with lung cancer are available at the RHTR. Among them, 255 donors (74%) are Mayak PA workers hired at the main facilities (reactors, plutonium production, and radiochemical plants) in 1948-1982. These workers donated about 6024 specimens of lung tissues (tumor and tumor-free) stored mostly as formalin-fixed paraffin-embedded tissue blocks (31%) and histology slides (64%); in addition, they donated 1800 specimens of blood/blood components, buccal epithelium cells, and sputum. Among histologic types identified for these lung cancer cases, adenocarcinoma and small cell carcinoma were prevalent. Information about individual doses from external and internal radiation exposure, data on quantitative smoking characteristics and diseases are available for all workers with lung cancer. Complete information on radiation exposure, health status and non-radiation factors annotated to RHTR registrants and the high quality of the available biological specimens are a unique resource for studying biological mechanisms of radiation-induced lung cancer.
Collapse
Affiliation(s)
- Galina Zhuntova
- Clinical Department, Southern Urals Biophysics Institute, Ozyorsk, Chelyabinsk Region, Russia
| | - Christopher Loffredo
- Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Evgeniya Grigoryeva
- Clinical Department, Southern Urals Biophysics Institute, Ozyorsk, Chelyabinsk Region, Russia
| | - Gleb Sychugov
- Clinical Department, Southern Urals Biophysics Institute, Ozyorsk, Chelyabinsk Region, Russia
| | - Evgeny Kazachkov
- Clinical Department, Southern Urals Biophysics Institute, Ozyorsk, Chelyabinsk Region, Russia
| | - Evgeniya Kirillova
- Clinical Department, Southern Urals Biophysics Institute, Ozyorsk, Chelyabinsk Region, Russia
| | - Tamara Azizova
- Clinical Department, Southern Urals Biophysics Institute, Ozyorsk, Chelyabinsk Region, Russia
| |
Collapse
|
27
|
Lieberman-Cribbin W, Tuminello S, Gillezeau C, van Gerwen M, Brody R, Mulholland DJ, Horton L, Sisco M, Prophete C, Zelikoff J, Lee HW, Park SH, Chen LC, Cohen MD, Taioli E. Complementary biobank of rodent tissue samples to study the effect of World Trade Center exposure on cancer development. J Transl Med 2019; 17:342. [PMID: 31601237 PMCID: PMC6788109 DOI: 10.1186/s12967-019-2089-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2019] [Accepted: 09/29/2019] [Indexed: 02/03/2023] Open
Abstract
World Trade Center (WTC) responders were exposed to mixture of dust, smoke, chemicals and carcinogens. New York University (NYU) and Mount Sinai have recreated WTC exposure in rodents to observe the resulting systemic and local biological responses. These experiments aid in the interpretation of epidemiological observations and are useful for understanding the carcinogenesis process in the exposed human WTC cohort. Here we describe the implementation of a tissue bank system for the rodents experimentally exposed to WTC dust. NYU samples were experimentally exposed to WTC dust via intratracheal inhalation that mimicked conditions in the immediate aftermath of the disaster. Tissue from Mount Sinai was derived from genetically modified mice exposed to WTC dust via nasal instillation. All processed tissues include annotations of the experimental design, WTC dust concentration/dose, exposure route and duration, genetic background of the rodent, and method of tissue isolation/storage. A biobank of tissue from rodents exposed to WTC dust has been compiled representing an important resource for the scientific community. The biobank remains available as a scientific resource for future research through established mechanisms for samples request and utilization. Studies using the WTC tissue bank would benefit from confirming their findings in corresponding tissues from organs of animals experimentally exposed to WTC dust. Studies on rodent tissues will advance the understanding of the biology of the tumors developed by WTC responders and ultimately impact the modalities of treatment, and the probability of success and survival of WTC cancer patients.
Collapse
Affiliation(s)
- Wil Lieberman-Cribbin
- Institute for Translational Epidemiology and Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1133, New York, NY, 10029, USA
| | - Stephanie Tuminello
- Institute for Translational Epidemiology and Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1133, New York, NY, 10029, USA
| | - Christina Gillezeau
- Institute for Translational Epidemiology and Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1133, New York, NY, 10029, USA
| | - Maaike van Gerwen
- Institute for Translational Epidemiology and Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1133, New York, NY, 10029, USA
| | - Rachel Brody
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - David J Mulholland
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Lori Horton
- Nelson Institute of Environmental Medicine, New York University, Tuxedo Park, NY, USA
| | - Maureen Sisco
- Nelson Institute of Environmental Medicine, New York University, Tuxedo Park, NY, USA
| | - Colette Prophete
- Nelson Institute of Environmental Medicine, New York University, Tuxedo Park, NY, USA
| | - Judith Zelikoff
- Nelson Institute of Environmental Medicine, New York University, Tuxedo Park, NY, USA
| | - Hyun-Wook Lee
- Nelson Institute of Environmental Medicine, New York University, Tuxedo Park, NY, USA
| | - Sung-Hyun Park
- Nelson Institute of Environmental Medicine, New York University, Tuxedo Park, NY, USA
| | - Lung-Chi Chen
- Nelson Institute of Environmental Medicine, New York University, Tuxedo Park, NY, USA
| | - Mitchell D Cohen
- Nelson Institute of Environmental Medicine, New York University, Tuxedo Park, NY, USA
| | - Emanuela Taioli
- Institute for Translational Epidemiology and Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1133, New York, NY, 10029, USA.
| |
Collapse
|
28
|
Suarez A, Reilly C, Fajgenbaum DC. Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent era. Orphanet J Rare Dis 2019; 14:173. [PMID: 31296233 PMCID: PMC6625003 DOI: 10.1186/s13023-019-1145-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 06/25/2019] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND Castleman disease (CD) describes a group of rare and poorly understood lymphoproliferative disorders that include unicentric CD (UCD), Human Herpes Virus-8 (HHV8)-associated multicentric CD (HHV8 + MCD), and HHV8-negative/idiopathic MCD (iMCD). Efforts to advance research and drug discovery for CD have been slowed by challenges shared by other rare diseases, such as collecting and centralizing data and biospecimens for research. To collect disease characteristic data and identify individuals interested in contributing biospecimens for research, a global research organization - the Castleman Disease Collaborative Network (CDCN) - established an international Contact Database and electronic repository (E-repository). Herein, we performed analyses of these datasets to further characterize CD and gain insights into research biospecimen acquisition. RESULTS Descriptive statistical analyses were performed on 891 participants from the Contact Database and 166 patients in the E-repository. The median age of patients at the time of enrollment in the Contact Database and E-repository was 42 ± 15.7 and 35 ± 14.8, respectively. The E-repository had increased representation from patients with MCD and the iMCD subtype compared to other sub-groups. Though the majority of participants were from the USA, a total of 49 countries on 6 continents were represented. Several patient characteristics in the Contact Database were associated with subsequent enrollment in the E-repository. There were significantly more MCD patients (p < 0.0001) and females (p = 0.002) enrolled in the E-repository compared to the Contact Database. Patient's year of birth, date of registration, preferred method of communication, and relationship to the patient were also significantly associated with enrollment in the e-Repository. CONCLUSIONS This study of the largest- dataset of CD patients worldwide provides insights into disease phenotypes, characteristics of patients interested in contributing data and biospecimens for research, and methods for successfully acquiring data and biospecimens. Generally, the factors associated with enrollment in the E-repository represented severity of disease subtype, proximity to the research, and patient motivation. We hope that these findings and the sample documentation (e.g., electronic consent, recruitment materials) provided with this article will assist future rare disease efforts with overcoming hurdles.
Collapse
Affiliation(s)
- Alexander Suarez
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
| | - Curran Reilly
- Castleman Disease Collaborative Network, Philadelphia, PA USA
| | - David C. Fajgenbaum
- Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
| |
Collapse
|
29
|
Abstract
Biobanks are critical resources for biomedical research and will be a driving force behind personalized medicine. Although biobanking efforts are increasing across the USA and the world, minority populations are frequently underrepresented in biobanks, which undermines their value. A number of factors have been linked to low rates of minority participation in biobanks, including mistrust of researchers, concerns about privacy and confidentiality, logistical barriers to participation, and inadequate opportunities to participate. There are several strategies biobankers can use to increase participation of minority and underserved populations and optimize the value of their biospecimen collection for research.
Collapse
|
30
|
Petas A, Erickson A, Santti H, Matikainen M, Mirtti T, Rannikko A. Fast prostate retrieval in robot-assisted laparoscopic prostatectomy for next-generation biobanking. J Robot Surg 2020; 14:271-4. [PMID: 31129776 DOI: 10.1007/s11701-019-00974-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2019] [Accepted: 05/14/2019] [Indexed: 10/26/2022]
Abstract
Robotic-assisted laparoscopic radical prostatectomy (RALP) has become the most widespread treatment for organ-confined prostate cancer. Here, we describe a fast specimen retrieval technique for RALP to obtain high-quality tissue specimen with minimal warm ischemia time for next-generation biobanking. Here, we show that using fast retrieval technique, short warm ischemia times can be achieved while not increasing the surgical time. Patients undergoing RALP with written informed consent participated in Helsinki Urological Bank study. Previously operated RALP patients and those, who were not willing to participate in the study, served as a control group. The study consisted of 1685 patients, 684 in fast retrieval and 1001 in control group. We developed a novel fast retrieval technique in which fascia is opened for camera port according to the prostate size and a running suture is placed and tightened against the camera port in the beginning of the operation. Immediately after prostate is freed from attachments, suture is loosened and the prostate is extirpated inside the endoscopic bag through the camera port fascial opening, then the fascial suture is again tightened against the camera port and the RALP procedure is completed. The mean warm ischemia times in fast retrieval group were 20 min 18 s and 22 min 30 s, respectively, in patients without and with lymphadenectomy. The mean console and surgery times with and without lymphadenectomy were similar in both groups. There were no technique-related complications associated with Fast Retrieval procedure. Tissue integrity test results for the RNA and DNA quality showed good quality for the specimen. Fast retrieval technique can easily and safely be utilized to maximize usefulness of RALP tissue specimen in downstream biobank applications.
Collapse
|
31
|
Abstract
Urine is a major repository of biometabolites, some proteins, and DNA. Within the past few decades, it has become increasingly apparent that certain infectious, neoplastic, and congenital diseases can be investigated using urine samples for diagnostic and prognostic purposes. In this chapter, a number of pertinent urine analytes and methods of banking urine samples for future analyses are discussed.
Collapse
|
32
|
Abstract
Biobanks support medical research by facilitating access to biospecimens. Biospecimens that are linked to clinical and molecular information are particularly useful for translational biomedical research. Tracking and managing the biospecimens and their associated data are therefore crucial tasks in the functioning of a biobank. Adequate computing hardware, efficient and comprehensive biobanking software, and cost-effective data storage are needed for proper management of biospecimens. As biobanks build up extensive stores of specimens and patient data, ethical considerations also inevitably arise. Herein, we describe some basic considerations for establishing a biobanking information technology infrastructure that a beginning biobanker needs. Finally, we also discuss trends and future needs in biobanking informatics.
Collapse
|
33
|
Abstract
A biobank is an important nexus between clinical and research aspects of pathology. The collection and storage of high quality surgical samples is essential for diagnosis post-surgery, and can also be used to create vaccines, identify therapeutic targets or establish eligibility of cancer patients in a clinical trial. Therefore, personnel handling surgical tissues should follow standard operating procedures (SOP) to maximize efficiency and preserve tissue quality. This chapter is intended to familiarize novice biobank personnel with the issues associated with different steps of surgical tissue collection including patient consent, sample collection, tissue storage, quality control, and distribution.
Collapse
Affiliation(s)
- Amin Hojat
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Bowen Wei
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Madeline G Olson
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Qinwen Mao
- Department of Pathology and Laboratory Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - William H Yong
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- Brain Tumor Translational Resource, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
| |
Collapse
|
34
|
Abstract
The purpose of a biobank is to process, organize, and maintain various types of biospecimens that are to be utilized for both clinical and research-based services. There are different types of biobanks, so the goals of the biobank should be delineated at the outset of forming a biobank. The startup of a biobank benefits from accreditation and stringent adherence to standards of practice. Fundamental to these practices is the protection of privacy and informed consent. A budget must be developed, and sources of funding should be obtained to properly equip the designated space and personnel. The appropriate space for freezers and for biospecimen processing should be identified. Information technology is also a critical part of the biobank and effort should be expended to ensure that this aspect is effective and secure. Given the ethical concerns surrounding biospecimens, engagement with the public is also highly valuable.
Collapse
Affiliation(s)
- Mitra D Harati
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Ryan R Williams
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Masoud Movassaghi
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Amin Hojat
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Gregory M Lucey
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - William H Yong
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. .,Brain Tumor Translational Resource, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. .,Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
| |
Collapse
|
35
|
Abstract
The personnel who operate a biomedical biobank should function as a unit to efficiently manage the numerous types of biospecimens that are to be utilized for both clinical and research purposes. Therefore, new staff must be appropriately trained before becoming fully integrated into the work environment. This chapter focuses on several key aspects to this training that should be completed by all personnel. This first step is an orientation where the new trainee is provided with the priorities and expectations of the biobank. The next and perhaps most important step is training on the various safety precautions. The trainee should learn how to protect patient privacy if human biospecimens are involved. They should gain a basic understanding of different types of biospecimens and their vulnerabilities to suboptimal storage conditions. The trainee must learn the various aspects of the day to day work which encompasses the methods and equipment needed for procuring, labeling, handling, tracking, storing, disbursing, and shipping biospecimens. They should become familiar with aspects of quality assurance.
Collapse
Affiliation(s)
- Ryan R Williams
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Diviya Gupta
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - William H Yong
- Division of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- Brain Tumor Translational Resource, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
| |
Collapse
|
36
|
Marchevsky AM, Bose S, Knudsen B. Procurement and Storage of Pleural and Peritoneal Fluids for Biobanking. Methods Mol Biol 2019; 1897:125-33. [PMID: 30539441 DOI: 10.1007/978-1-4939-8935-5_13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register]
Abstract
There is limited information regarding the biobanking of pleural and peritoneal fluids that might supplement storage of pulmonary and thoracic tissue biospecimens. Such fluids are sometimes collected for clinical analyses and may have uses that obviate or supplement tissue samples. There has been a growing interest in using liquid biopsies as they are less invasive and may be amenable to analyses that guide targeted therapies. Integrating cytology and biobanking approaches, we describe techniques that may be used for collecting and banking pleural and peritoneal fluids.
Collapse
|
37
|
Muglia P, Filosi M, Da Ros L, Kam-Thong T, Nardocci F, Trabetti E, Ratti E, Rizzini P, Zuddas A, Bernardina BD, Domenici E. The Italian autism network (ITAN): a resource for molecular genetics and biomarker investigations. BMC Psychiatry 2018; 18:369. [PMID: 30463616 PMCID: PMC6247619 DOI: 10.1186/s12888-018-1937-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Accepted: 10/23/2018] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND A substantial genetic component accounts for Autism Spectrum Disorders (ASD) aetiology, with some rare and common genetic risk factors recently identified. Large collections of DNAs from thoroughly characterized ASD families are an essential step to confirm genetic risk factors, identify new variants and investigate genotype-phenotype correlations. The Italian Autism Network aimed at constituting a clinical database and a biorepository of samples derived from ASD subjects and first-degree relatives extensively and consistently characterized by child psychiatry centers in Italy. METHODS The study was approved by the ethical committee of the University of Verona, the coordinating site, and by the local ethical committees of each recruiting site. Certified staff was specifically trained at each site for the overall study conduct, for clinical protocol administration and handling of biological material. A centralized database was developed to collect clinical assessment and medical records from each recruiting site. Children were eligible for recruitment based on the following inclusion criteria: age 4-18 years, at least one parent or legal guardian giving voluntary written consent, meeting DSM-IV criteria for Autistic Disorder or Asperger's Disorder or Pervasive Developmental Disorder NOS. Affected individuals were assessed by full psychiatric, neurological and physical examination, evaluation with ADI-R and ADOS scales, cognitive assessment with Wechsler Intelligence Scale for Children or Preschool and Primary, Leiter International Performance Scale or Griffiths Mental Developmental Scale. Additional evaluations included language assessment, the Krug Asperger's Disorder Index, and instrumental examination such as EEG and structural MRI. DNA, RNA and plasma were collected from eligible individuals and relatives. A central laboratory was established to host the biorepository, perform DNA and RNA extraction and lymphocytes immortalisation. DISCUSSION The study has led to an extensive collection of biological samples associated with standardised clinical assessments from a network of expert clinicians and psychologists. Eighteen sites have received ADI/ADOS training, thirteen of which have been actively recruiting. The clinical database currently includes information on 812 individuals from 249 families, and the biorepository has samples for 98% of the subjects. This effort has generated a highly valuable resource for conducting clinical and genetic research of ASD, amenable to further expansion.
Collapse
Affiliation(s)
| | - Michele Filosi
- 0000 0004 1937 0351grid.11696.39Centre for Integrative Biology, University of Trento, Trento, Italy
| | | | - Tony Kam-Thong
- Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Grenzacherstrasse 124, Basel, Switzerland
| | | | - Elisabetta Trabetti
- 0000 0004 1763 1124grid.5611.3Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy
| | - Emiliangelo Ratti
- 0000 0004 0447 7762grid.419849.9Central Nervous System (CNS) Therapeutic Area Unit, Takeda, Boston, USA
| | | | - Alessandro Zuddas
- 0000 0004 1755 3242grid.7763.5Child and Adolescent Psychiatry Unit, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy
| | - Bernardo Dalla Bernardina
- Servizio di Neuropsichiatria Infantile Azienda Ospedaliera Istituti Ospitalieri di Verona Policlinico G.B. Rossi, Verona, Italy
| | - Enrico Domenici
- Centre for Integrative Biology, University of Trento, Trento, Italy. .,The Microsoft Research - University of Trento Centre for Computational and Systems Biology, Rovereto, TN, Italy.
| | | |
Collapse
|
38
|
Lieberman-Cribbin W, Tuminello S, Gillezeau C, van Gerwen M, Brody R, Donovan M, Taioli E. The development of a Biobank of cancer tissue samples from World Trade Center responders. J Transl Med 2018; 16:280. [PMID: 30309352 PMCID: PMC6182816 DOI: 10.1186/s12967-018-1661-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Accepted: 10/09/2018] [Indexed: 11/24/2022] Open
Abstract
Background World Trade Center (WTC) responders were exposed to mixture of dust, smoke, chemicals and carcinogens. Studies of cancer incidence in this population have reported elevated risks of cancer compared to the general population. There is a need to supplement current epidemiologic cancer follow-up with a cancer tissue bank in order to better elucidate a possible connection between each cancer and past WTC exposure. This work describes the implementation of a tissue bank system for the WTC newly diagnosed cancers, focused on advancing the understanding of the biology of these tumors. This will ultimately impact the modalities of treatment, and the probability of success and survival of these patients. Methods WTC Responders who participated (as employees or volunteers) in the rescue, recovery and cleanup efforts at the WTC sites have been enrolled at Mount Sinai in the World Trade Center Health Program. Responders with cancer identified and validated through linkages with New York, New Jersey, Pennsylvania, and Connecticut cancer registries were eligible to participate in this biobank. Potential participants were contacted through letters, phone calls, and emails to explain the research study, consent process, and to obtain the location where their cancer procedure was performed. Pathology departments were contacted to identify and request tissue samples. Results All the 866 solid cancer cases confirmed by the Data Center at Mount Sinai have been contacted and consent was requested for retrieval and storage of the tissue samples from their cancer. Hospitals and doctors’ offices were then contacted to locate and identify the correct tissue block for each patient. The majority of these cases consist of archival paraffin blocks from surgical patients treated from 2002 to 2015. At the time of manuscript writing, this resulted in 280 cancer samples stored in the biobank. Conclusions A biobank of cancer tissue from WTC responders has been compiled with 280 specimens in storage to date. This tissue bank represents an important resource for the scientific community allowing for high impact studies on environmental exposures and cancer etiology, cancer outcome, and gene-environment interaction in the unique population of WTC responders.
Collapse
Affiliation(s)
- Wil Lieberman-Cribbin
- Department of Population Health Science and Policy and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1133, New York, NY, 10029, USA
| | - Stephanie Tuminello
- Department of Population Health Science and Policy and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1133, New York, NY, 10029, USA
| | - Christina Gillezeau
- Department of Population Health Science and Policy and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1133, New York, NY, 10029, USA
| | - Maaike van Gerwen
- Department of Population Health Science and Policy and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1133, New York, NY, 10029, USA
| | - Rachel Brody
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Michael Donovan
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Emanuela Taioli
- Department of Population Health Science and Policy and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1133, New York, NY, 10029, USA.
| |
Collapse
|
39
|
Abstract
Biobanks play an increasing role in contemporary research projects. These units meet all requirements to regard them as a one of the most innovative and up-to-date in the field of biomedical research. They enable conducting wide-scale research by the professional collection of biological specimens and correlated clinical data. Pathology units may be perceived roots of biobanking. The review aims at describing the concept of biobanks, their model of function and scientific potential. It comprises the division of biobanks, sample preservation methods and IT solutions as well as guidelines and recommendations for management of a vast number of biological samples and clinical data. Therefore, appropriate standard operating procedures and protocols are outlined. Constant individualization of diagnostic process and treatment procedures creates the niche for translational units. Thus, the role of biobanks in personalized medicine was also specified. The exceptionality of biobanks poses some new ethical-legal issues which have various solutions, in each legal system, amongst the world. Finally, distribution and activity of European biobanks are mentioned.
Collapse
Affiliation(s)
- Wiktor Paskal
- The Department of Histology and Embryology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, ul. Banacha 1B, 02-097, Warsaw, Poland.
- Plastic Surgery Department, Centre of Postgraduate Medical Education, Warsaw, Poland.
- The Department of Applied Pharmacy, Medical University of Warsaw, Warsaw, Poland.
| | - Adriana M Paskal
- The Department of Histology and Embryology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, ul. Banacha 1B, 02-097, Warsaw, Poland
| | - Tomasz Dębski
- Plastic Surgery Department, Centre of Postgraduate Medical Education, Warsaw, Poland
| | - Maciej Gryziak
- The Department of Applied Pharmacy, Medical University of Warsaw, Warsaw, Poland
- Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland
| | - Janusz Jaworowski
- The Department of Applied Pharmacy, Medical University of Warsaw, Warsaw, Poland
| |
Collapse
|
40
|
Ruíz-Godoy LM, Baez-Revueltas FB, de Lourdes Suarez-Roa M, Maldonado-Martínez H, Enriquez-Carcamo V, Colín-González AL, Meneses-García A. A pharmacoeconomic analysis of the collection and preservation of samples in the biobank of the "Instituto Nacional de Cancerología" in Mexico City. Cell Tissue Bank 2018; 19:569-580. [PMID: 30155658 DOI: 10.1007/s10561-018-9706-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Accepted: 06/20/2018] [Indexed: 10/28/2022]
Abstract
In this work we estimated the budgetary impact of the samples produced by the biobank of the "Instituto Nacional de Cancerología" (BT-INCan) to set a recuperation fee from the perspective of the Health Ministry of Mexico. The study is an observational retrospective review of the direct medical costs (DMCs) of the processes involved in cryopreservation of the samples collected, on a per sample basis, including materials, laboratory tests, personnel, and administrative costs. Materials and labor costs were determined by information collected from the BT-INCan. DMCs were provided depending on the type of sample: plasma, tissue and biopsy; they were calculated according to the process required to preserve them. Sensitivity analysis was performed using bootstrap. Recuperation costs ranged from 130 to 155 USD. Costs were considered on a 5-year time frame for the maintenance per sample, which is the average time that a sample is kept in the BT-INCan. The cost analysis is perceived as an approximation to the most adequate recuperation fee per sample needed to guarantee the correct development of the BT-INCan. This work provides a basis and valuable information about costs, to enable several health institutions to strategically plan and manage a biobank or even motivate to establish their own biobank.
Collapse
Affiliation(s)
- Luz María Ruíz-Godoy
- Banco de Tumores, Instituto Nacional de Cancerología, S.S.A., 14080, Mexico City, Mexico
| | | | | | | | | | | | - Abelardo Meneses-García
- Dirección General, Instituto Nacional de Cancerología, S.S.A. San Fernando 22 Col. Sección XVI, Tlalpan, C.P. 14080, Mexico City, Mexico.
| |
Collapse
|
41
|
Raspa M, Fray M, Paoletti R, Montoliu L, Giuliani A, Scavizzi F. A new, simple and efficient liquid nitrogen free method to cryopreserve mouse spermatozoa at -80 °C. Theriogenology 2018; 119:52-59. [PMID: 29982136 DOI: 10.1016/j.theriogenology.2018.06.020] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 05/28/2018] [Accepted: 06/24/2018] [Indexed: 11/26/2022]
Abstract
The mouse is widely used for biomedical research and an increasing number of genetically altered models are currently generated, therefore centralized repositories are essentials to secure the important mouse strains that have been developed. We have previously reported that spermatozoa of wild type and mutant strains frozen using standard laboratory protocols can be transported in dry ice (-79 °C) for 7 days and safely stored in a -80 °C freezer for up to two years. The objective of this new study was to compare the effects of the freezing techniques using LN2 or -80 °C freezer on fertility of frozen-thawed mouse spermatozoa. After thawing, sperm fertility was comparable (P > 0,05) between the LN2 and the -80 °C samples for at least 1 year. Furthermore, we showed that it is possible to freeze and store mouse semen directly at -80 °C and eventually transfer it to LN2 irrespective of storage time. This study is relevant because it shows for the first time that mouse spermatozoa can be efficiently frozen and stored at -80 °C with no use of liquid nitrogen for a long period of time. A new, simple, efficient and flexible, liquid nitrogen free, method was developed for freezing and maintaining spermatozoa of wild type and mutant C57BL/6N lines. Lines on this genetic background are used in collaborative research infrastructures for systematic phenotyping, e.g. the International Mouse Phenotyping Consortium (IMPC) and therefore largely cryopreserved in repositories like EMMA/Infrafrontier. The importance of this finding will be especially useful for small laboratories with no or limited access to liquid nitrogen and for laboratories generating many mouse mutant lines by CRISPR/Cas9 who do not want to saturate the limited space of a LN2 tank, using a more accessible -80 °C freezer. This study underlines, once more, that mouse spermatozoa are very resistant and can be frozen, transported, shared and stored at -80 °C for a long time without a significant loss of viability. This new approach simplifies the freezing process and facilitates the long term storage of mouse spermatozoa at -80 °C, always allowing the transfer to LN2 for indefinite storage without noticeable detrimental effects.
Collapse
Affiliation(s)
- Marcello Raspa
- National Research Council (IBCN), CNR-Campus International Development (EMMA-INFRAFRONTIER-IMPC), Monterotondo Scalo, Rome, Italy
| | - Martin Fray
- Mary Lyon Centre, MRC Harwell Institute, Harwell Campus, Oxfordshire, OX11 0RD, United Kingdom
| | | | - Lluis Montoliu
- National Centre for Biotechnology (CNB-CSIC), Department of Molecular and Cellular Biology, Campus de Cantoblanco, Darwin 3, 28049, Madrid, Spain; CIBERER-ISCIII, Madrid, Spain
| | | | | | - Ferdinando Scavizzi
- National Research Council (IBCN), CNR-Campus International Development (EMMA-INFRAFRONTIER-IMPC), Monterotondo Scalo, Rome, Italy.
| |
Collapse
|
42
|
Compadre AJ, Simonson ME, Gray K, Runnells G, Kadlubar S, Zorn KK. Challenges in recruiting African-American women for a breast cancer genetics study. Hered Cancer Clin Pract 2018; 16:8. [PMID: 29760829 PMCID: PMC5937804 DOI: 10.1186/s13053-018-0091-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Accepted: 04/05/2018] [Indexed: 11/20/2022] Open
Abstract
Background African-American women, especially in the southern United States, are underrepresented in cancer genetics research. A study was designed to address this issue by investigating the germline mutation rate in African-American women in Arkansas with a personal and/or family history of breast cancer. Women were tested for these mutations using a large panel of breast cancer susceptibility genes. In this analysis, we discuss the challenges encountered in recruiting African-American women from an existing biorepository to participate in this study. Methods We attempted to contact 965 African-American women with a personal and/or family history of breast cancer who participated in Spit for the Cure (SFTC) between 2007 and 2013 and provided consent to be recontacted. The SFTC participants were invited by telephone and email to participate in the genetic study. Enrollment required completion of a phone interview to obtain a family and medical history and return of a signed consent form. Results Among eligible SFTC participants, 39.6% (382/965) were able to be contacted with the phone numbers and email addresses they provided. Of these, 174 (45.5%) completed a phone interview and returned a signed consent form. Others were not able to be contacted (n = 583), declined to participate (n = 57), did not keep phone interview appointments (n = 82), completed the phone interview but never returned a signed consent (n = 54), were deceased (n = 13), or were too confused to consent to participate (n = 2). Conclusions Recruiting African-American women into our breast cancer genetics study proved challenging primarily due to difficulty establishing contact with potential participants. Given their prior participation in breast cancer research, we anticipated that this would be a highly motivated population. Indeed, when we were able to contact SFTC participants, only 14.9% declined to participate in our study. Innovative communication, retention, and recruitment strategies are needed in future studies to address the recruitment challenges we faced.
Collapse
Affiliation(s)
- Amanda J Compadre
- 1Division of Gynecologic Oncology, College of Medicine, University of Arkansas for Medical Sciences, 4301 W Markham St. Slot 793, Little Rock, AR 72205 USA
| | - Melinda E Simonson
- 1Division of Gynecologic Oncology, College of Medicine, University of Arkansas for Medical Sciences, 4301 W Markham St. Slot 793, Little Rock, AR 72205 USA
| | - Katy Gray
- 1Division of Gynecologic Oncology, College of Medicine, University of Arkansas for Medical Sciences, 4301 W Markham St. Slot 793, Little Rock, AR 72205 USA
| | - Gail Runnells
- 2Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences, 4301 W Markham St., Little Rock, AR 72205 USA
| | - Susan Kadlubar
- 2Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences, 4301 W Markham St., Little Rock, AR 72205 USA
| | - Kristin K Zorn
- 1Division of Gynecologic Oncology, College of Medicine, University of Arkansas for Medical Sciences, 4301 W Markham St. Slot 793, Little Rock, AR 72205 USA
| |
Collapse
|
43
|
Viswanath B, Rao NP, Narayanaswamy JC, Sivakumar PT, Kandasamy A, Kesavan M, Mehta UM, Venkatasubramanian G, John JP, Mukherjee O, Purushottam M, Kannan R, Mehta B, Kandavel T, Binukumar B, Saini J, Jayarajan D, Shyamsundar A, Moirangthem S, Vijay Kumar KG, Thirthalli J, Chandra PS, Gangadhar BN, Murthy P, Panicker MM, Bhalla US, Chattarji S, Benegal V, Varghese M, Reddy JYC, Raghu P, Rao M, Jain S. Discovery biology of neuropsychiatric syndromes (DBNS): a center for integrating clinical medicine and basic science. BMC Psychiatry 2018; 18:106. [PMID: 29669557 PMCID: PMC5907468 DOI: 10.1186/s12888-018-1674-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Accepted: 03/21/2018] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND There is emerging evidence that there are shared genetic, environmental and developmental risk factors in psychiatry, that cut across traditional diagnostic boundaries. With this background, the Discovery biology of neuropsychiatric syndromes (DBNS) proposes to recruit patients from five different syndromes (schizophrenia, bipolar disorder, obsessive compulsive disorder, Alzheimer's dementia and substance use disorders), identify those with multiple affected relatives, and invite these families to participate in this study. The families will be assessed: 1) To compare neuro-endophenotype measures between patients, first degree relatives (FDR) and healthy controls., 2) To identify cellular phenotypes which differentiate the groups., 3) To examine the longitudinal course of neuro-endophenotype measures., 4) To identify measures which correlate with outcome, and 5) To create a unified digital database and biorepository. METHODS The identification of the index participants will occur at well-established specialty clinics. The selected individuals will have a strong family history (with at least another affected FDR) of mental illness. We will also recruit healthy controls without family history of such illness. All recruited individuals (N = 4500) will undergo brief clinical assessments and a blood sample will be drawn for isolation of DNA and peripheral blood mononuclear cells (PBMCs). From among this set, a subset of 1500 individuals (300 families and 300 controls) will be assessed on several additional assessments [detailed clinical assessments, endophenotype measures (neuroimaging- structural and functional, neuropsychology, psychophysics-electroencephalography, functional near infrared spectroscopy, eye movement tracking)], with the intention of conducting repeated measurements every alternate year. PBMCs from this set will be used to generate lymphoblastoid cell lines, and a subset of these would be converted to induced pluripotent stem cell lines and also undergo whole exome sequencing. DISCUSSION We hope to identify unique and overlapping brain endophenotypes for major psychiatric syndromes. In a proportion of subjects, we expect these neuro-endophenotypes to progress over time and to predict treatment outcome. Similarly, cellular assays could differentiate cell lines derived from such groups. The repository of biomaterials as well as digital datasets of clinical parameters, will serve as a valuable resource for the broader scientific community who wish to address research questions in the area.
Collapse
Affiliation(s)
- Biju Viswanath
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Naren P. Rao
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | | | | | - Arun Kandasamy
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Muralidharan Kesavan
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | | | | | - John P. John
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Odity Mukherjee
- Institute for Stem Cell Biology and Regenerative Medicine (InStem), Bangalore, India
| | - Meera Purushottam
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Ramakrishnan Kannan
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Bhupesh Mehta
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Thennarasu Kandavel
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - B. Binukumar
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Jitender Saini
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Deepak Jayarajan
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - A. Shyamsundar
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Sydney Moirangthem
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - K. G. Vijay Kumar
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Jagadisha Thirthalli
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Prabha S. Chandra
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | | | - Pratima Murthy
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Mitradas M. Panicker
- National Centre for Biological Sciences, Tata Institute of Fundamental Research (NCBS-TIFR), Bangalore, India
| | - Upinder S. Bhalla
- National Centre for Biological Sciences, Tata Institute of Fundamental Research (NCBS-TIFR), Bangalore, India
| | - Sumantra Chattarji
- Institute for Stem Cell Biology and Regenerative Medicine (InStem), Bangalore, India
- National Centre for Biological Sciences, Tata Institute of Fundamental Research (NCBS-TIFR), Bangalore, India
| | - Vivek Benegal
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | - Mathew Varghese
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| | | | - Padinjat Raghu
- National Centre for Biological Sciences, Tata Institute of Fundamental Research (NCBS-TIFR), Bangalore, India
| | - Mahendra Rao
- Institute for Stem Cell Biology and Regenerative Medicine (InStem), Bangalore, India
| | - Sanjeev Jain
- National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India
| |
Collapse
|
44
|
Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. Biol Blood Marrow Transplant 2018; 24:1727-1732. [PMID: 29476954 DOI: 10.1016/j.bbmt.2018.02.010] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Accepted: 02/08/2018] [Indexed: 11/26/2022]
Abstract
In 2014, the National Institutes of Health sponsored the second Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease (GVHD). The purpose was to update recommendations about key elements of chronic GVHD research, including definitions for diagnosis, severity scoring, and response measures, based on empirical data published since the first 2005 Consensus Conference. The most significant modifications were to the response assessments, based on studies demonstrating difficulty with the first consensus definitions. The Response Measures Validation Study is a multicenter, prospective cohort study of patients who are starting initial or subsequent treatments for chronic GVHD. The aim of the study is to evaluate the performance of the 2014 response measures and determine whether any other combination of assessments is superior. Clinical data, clinician assessments, patient-reported outcomes, and research samples are collected at enrollment and 3, 6, and 18 months later, and whenever another chronic GVHD systemic treatment is added. The target enrollment of 368 evaluable patients from 12 transplantation centers has been reached. This report describes the rationale, design, and methods of the Chronic GVHD Response Measures Validation Study, and invites other investigators to collaborate with the Consortium to analyze data or specimens.
Collapse
|
45
|
Abstract
Necrotizing enterocolitis (NEC) is a devastating disease affecting premature infants. New advances in diagnostic and treatment options are desperately needed. Accordingly, the NEC Society initiated a research collaborative with a group of investigators dedicated to advancing the state of NEC-associated knowledge. Recent advances in high-content molecular interrogation and bio-computation (e.g., genomics, transcriptomics, proteomics, and metabolomics) can provide new insights from afflicted infants with NEC, however, individual centers do not have sufficient cases to conduct these studies independently. The development of a NEC Society Biorepository (NSB) has emerged to advance collaboration among institutions through the shared use of biologic samples in the dedicated pursuit of molecular indicators of disease and to gain greater pathophysiologic insights through research. The NSB will provide key infrastructure across several centers to harness the potential for new discoveries, while ensuring specimens are processed consistently, appropriate clinical data is collected, and privacy is maintained. The NSB will provide a comprehensive framework for sharing biological samples and clinical data through a robust and secure system that supports the investigation of research studies on NEC.
Collapse
Affiliation(s)
- Matthew W. Ralls
- Section of Pediatric Surgery, Department of Surgery, University of Michigan Health System, Ann Arbor, MI, USA
| | - Samir K. Gadepalli
- Section of Pediatric Surgery, Department of Surgery, University of Michigan Health System, Ann Arbor, MI, USA
| | - Karl G. Sylvester
- Department of Surgery, Stanford University School of Medicine, Stanford, CA; Fetal and Maternal Health Program, Lucile Packard Children’s Hospital Stanford, Stanford, CA
| | - Misty Good
- Division of Newborn Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, 660 S. Euclid Ave, Campus Box 8208, St. Louis, Missouri 63110.
| |
Collapse
|
46
|
Drake BF, Brown KM, Gehlert S, Wolf LE, Seo J, Perkins H, Goodman MS, Kaphingst KA. Development of Plain Language Supplemental Materials for the Biobank Informed Consent Process. J Cancer Educ 2017; 32:836-844. [PMID: 27037699 PMCID: PMC5047847 DOI: 10.1007/s13187-016-1029-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The US Department of Health and Human Services addresses clear communication in the informed consent process as part of the Notice of Proposed Rulemaking for revisions to the Common Rule. However, prior research has shown that participants may not fully comprehend research studies despite completion of an informed consent process. Our main goal was to provide plain language information about donation processes to a cancer biobank to supplement an informed consent form. We developed and conducted cognitive testing with supplemental brochures that clearly communicated information about three different models for consent (notice, broad and study-specific) to future use of biospecimens. During the brochure development process, we conducted qualitative, semi-structured, individual, in-person cognitive interviews among 14 women to examine participants' perceptions of the brochures. Each participant provided feedback regarding the understandability, graphics and layout, and cultural appropriateness of the brochures. Our findings demonstrate that these methods may be used to tailor consent form brochures, such as the ones developed here, to other populations. This study therefore adds to our understanding of how best to present content to help women from two different racial groups make informed decisions about participation in a cancer biobank.
Collapse
Affiliation(s)
- Bettina F Drake
- Division of Public Health Sciences, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA.
- Alvin J. Siteman Cancer Center, St. Louis, MO, 63110, USA.
| | - Katherine M Brown
- Division of Public Health Sciences, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA
| | - Sarah Gehlert
- Division of Public Health Sciences, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA
- Alvin J. Siteman Cancer Center, St. Louis, MO, 63110, USA
| | - Leslie E Wolf
- Center for Law Health and Society, Georgia State University College of Law, 85 Park Place NE, Atlanta, GA, 30303, USA
| | - Joann Seo
- Division of Public Health Sciences, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA
| | - Hannah Perkins
- Division of Public Health Sciences, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA
| | - Melody S Goodman
- Division of Public Health Sciences, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA
- Alvin J. Siteman Cancer Center, St. Louis, MO, 63110, USA
| | - Kimberly A Kaphingst
- Department of Communication, University of Utah, 255 S. Central Campus Dr., Salt Lake City, UT, 84112-0491, USA
- Huntsman Cancer Institute, 2000 Circle of Hope Drive, Salt Lake City, UT, 84112, USA
| |
Collapse
|
47
|
Abstract
Before the burgeoning field of biospecimen collection can advance prevention and treatment methods, researchers must access diverse molecular data samples. However, minorities, especially African-American men, remain reticent to join these studies. This study, using theory-based approaches, investigated African-American men's barriers to participating in biorepository research. Fourteen focus groups were conducted among 70 African-American men (ages 40 to 80). The groups were stratified by prostate cancer history and educational attainment background. Participants identified perceived factors that promoted or hindered study participation when questioned about their knowledge and attitudes about biospecimen research. Ninety-four percent of participants indicated never participating in a study that collected biological samples. Barriers to their participation included lack of knowledge and understanding regarding biospecimen research practices and uses. In addition, they extensively cited a prevalent mistrust of the medical community and discomfort with study recruitment practices. African-American males were more willing to participate in biorepository studies with physician endorsement or if they understood that participation could benefit future generations. Men also wanted more recruitment and advertising done in familiar places.
Collapse
Affiliation(s)
- Bettina F. Drake
- Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO 63110 United States, Alvin J. Siteman Cancer Center, St. Louis, MO 63110, , phone: 314-747-4534, fax: 314454-7941
| | - Danielle Boyd
- Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO 63110 United States,
| | - Kimberly Carter
- Department of Social Work, Southern Illinois University-Edwardsville, Edwardsville, IL 62026 United States,
| | - Sarah Gehlert
- Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO 63110 United States, Alvin J. Siteman Cancer Center, St. Louis, MO 63110 United States,
| | - Vetta Sanders Thompson
- Brown School of Social Work, Washington University in St. Louis, St. Louis, MO 63110 United States,
| |
Collapse
|
48
|
Heredia NI, Krasny S, Strong LL, Von Hatten L, Nguyen L, Reininger BM, McNeill LH, Fernández ME. Community Perceptions of Biobanking Participation: A Qualitative Study among Mexican-Americans in Three Texas Cities. Public Health Genomics 2016; 20:46-57. [PMID: 27926908 DOI: 10.1159/000452093] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Accepted: 09/28/2016] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Most biospecimens in the US are collected from non-Hispanic Whites, limiting the generalizability of findings. There is a need to increase participation in biobanking among ethnic and racial minorities. The purpose of this study was to use qualitative methods to identify factors that may influence Mexican-American individuals' willingness to participate in biobanking. METHODS We conducted 15 focus groups in three Texas cities with Mexican-American individuals, in both Spanish and English. RESULTS Lack of knowledge about medical research and biobanks, lack of information about the specifics of biobanking participation, lack of communication of the results, fear of pain or harm, and distrust of the healthcare system or health research were identified as barriers to biobanking participation. Facilitators to participation were altruism, safety, understanding biobanking procedures and purposes, perceived benefits to participation, and culturally appropriate recruitment strategies. Although Mexican-Americans living in Texas are willing to donate biospecimens for altruistic reasons, such as helping society or advancing science, they want more information about what biobanking entails. They want to be assured that participation will not cause them harm and that the research is conducted with good intentions. CONCLUSION Results from this study can inform educational materials or interventions to increase Hispanic participation in biobanking.
Collapse
Affiliation(s)
- Natalia I Heredia
- School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Hedderson MM, Ferrara A, Avalos LA, Van den Eeden SK, Gunderson EP, Li DK, Altschuler A, Woo S, Rowell S, Choudhary V, Xu F, Flanagan T, Schaefer C, Croen LA. The Kaiser Permanente Northern California research program on genes, environment, and health (RPGEH) pregnancy cohort: study design, methodology and baseline characteristics. BMC Pregnancy Childbirth 2016; 16:381. [PMID: 27899076 PMCID: PMC5129213 DOI: 10.1186/s12884-016-1150-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2016] [Accepted: 11/08/2016] [Indexed: 11/16/2022] Open
Abstract
Background Exposures during the prenatal period may have lasting effects on maternal and child health outcomes. To better understand the effects of the in utero environment on children’s short- and long-term health, large representative pregnancy cohorts with comprehensive information on a broad range of environmental influences (including biological and behavioral) and the ability to link to prenatal, child and maternal health outcomes are needed. The Research Program on Genes, Environment and Health (RPGEH) pregnancy cohort at Kaiser Permanente Northern California (KPNC) was established to create a resource for conducting research to better understand factors influencing women’s and children’s health. Recruitment is integrated into routine clinical prenatal care at KPNC, an integrated health care delivery system. We detail the study design, data collection, and methodologies for establishing this cohort. We also describe the baseline characteristics and the cohort’s representativeness of the underlying pregnant population in KPNC. Methods While recruitment is ongoing, as of October 2014, the RPGEH pregnancy cohort included 16,977 pregnancies (53 % from racial and ethnic minorities). RPGEH pregnancy cohort participants consented to have blood samples obtained in the first trimester (mean gestational age 9.1 weeks ± 4.2 SD) and second trimester (mean gestational age 18.1 weeks ± 5.5 SD) to be stored for future use. Women were invited to complete a questionnaire on health history and lifestyle. Information on women’s clinical and health assessments before, during and after pregnancy and women and children’s health outcomes are available in the health system’s electronic health records, which also allows long-term follow-up. Discussion This large, racially- and ethnically-diverse cohort of pregnancies with prenatal biospecimens and clinical data is a valuable resource for future studies on in utero environmental exposures and maternal and child perinatal and long term health outcomes. The baseline characteristics of RPGEH Pregnancy Cohort demonstrate that it is highly representative of the underlying population living in the broader community in Northern California. Electronic supplementary material The online version of this article (doi:10.1186/s12884-016-1150-2) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- M M Hedderson
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA.
| | - A Ferrara
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| | - L A Avalos
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| | - S K Van den Eeden
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| | - E P Gunderson
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| | - D K Li
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| | - A Altschuler
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| | - S Woo
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| | - S Rowell
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| | - V Choudhary
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| | - F Xu
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| | - T Flanagan
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| | - C Schaefer
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| | - L A Croen
- Kaiser Permanente Northern California Division of Research, 2000 Broadway, Oakland, CA, 94612, USA
| |
Collapse
|
50
|
Drake BF, Brown K, McGowan LD, Haslag-Minoff J, Kaphingst K. Secondary consent to biospecimen use in a prostate cancer biorepository. BMC Res Notes 2016; 9:346. [PMID: 27431491 PMCID: PMC4949745 DOI: 10.1186/s13104-016-2159-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2016] [Accepted: 07/13/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Biorepository research has substantial societal benefits. This is one of the few studies to focus on male willingness to allow future research use of biospecimens. METHODS This study analyzed the future research consent questions from a prostate cancer biorepository study (N = 1931). The consent form asked two questions regarding use of samples in future studies (1) without and (2) with protected health information (PHI). Yes to both questions of use of samples was categorized as Yes-Always; Yes to without and No to with PHI was categorized as Yes-Conditional; No to without PHI was categorized as Never. We analyzed this outcome to determine significant predictors for consent to Yes-Always vs. Yes-Conditional. RESULTS 99.33 % consented to future use of samples; 88.19 % consented to future use without PHI, and among those men 10.2 % consented to future use with PHI. Comparing Yes Always and Yes Conditional responses, bivariate analyses showed that race, family history, stage of cancer, and grade of cancer (Gleason), were significant at the α = 0.05 level. Using stepwise multivariable logistic regression, we found that African-American men were significantly more likely to respond Yes Always when compared to White men (p < 0.001). Those with a family history of prostate cancer were significantly more likely to respond Yes Always (p = 0.002). CONCLUSIONS There is general willingness to consent to future use of specimens without PHI among men.
Collapse
Affiliation(s)
- Bettina F Drake
- Division of Public Health Sciences, Washington University School of Medicine, 600 S. Taylor Ave, Campus Box 8100, St. Louis, MO, 63110, USA. .,Alvin J. Siteman Cancer Center, St. Louis, MO, USA.
| | - Katherine Brown
- Division of Public Health Sciences, Washington University School of Medicine, 600 S. Taylor Ave, Campus Box 8100, St. Louis, MO, 63110, USA
| | | | | | - Kimberly Kaphingst
- Department of Communication, University of Utah, Salt Lake City, UT, USA.,Huntsman Cancer Institute, Salt Lake City, UT, USA
| |
Collapse
|